Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Breast Cancer Res Treat

Retrieve available abstracts of 551 articles:
HTML format
Text format



Single Articles


    October 2017
  1. ALTUNDAG K
    Duration of trastuzumab in HER2-positive metastatic breast cancer after complete remission: still debatable issue?
    Breast Cancer Res Treat. 2017 Oct 11. doi: 10.1007/s10549-017-4536.
    PubMed     Text format    


  2. DOMINICI LS, Sineshaw HM, Jemal A, Lin CC, et al
    Patterns of axillary evaluation in older patients with breast cancer and associations with adjuvant therapy receipt.
    Breast Cancer Res Treat. 2017 Oct 9. doi: 10.1007/s10549-017-4528.
    PubMed     Text format     Abstract available


  3. PAGE DB, Wen H, Brogi E, Dure D, et al
    Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact.
    Breast Cancer Res Treat. 2017 Oct 6. doi: 10.1007/s10549-017-4520.
    PubMed     Text format     Abstract available


  4. KAIDAR-PERSON O, Meattini I, Jain P, Bult P, et al
    Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study.
    Breast Cancer Res Treat. 2017 Oct 3. doi: 10.1007/s10549-017-4526.
    PubMed     Text format     Abstract available


    September 2017
  5. XIA J, Tang Z, Deng Q, Yang R, et al
    Predictors of the quality of life in Chinese breast cancer survivors.
    Breast Cancer Res Treat. 2017 Sep 30. doi: 10.1007/s10549-017-4512.
    PubMed     Text format     Abstract available


  6. GALLARDO A, Lerma E
    Response letter to: Questions about Ki67 staining in luminal breast cancer.
    Breast Cancer Res Treat. 2017 Sep 27. doi: 10.1007/s10549-017-4524.
    PubMed     Text format    


  7. ALTUNDAG K
    Questions about Ki67 staining in luminal breast cancer.
    Breast Cancer Res Treat. 2017 Sep 27. doi: 10.1007/s10549-017-4515.
    PubMed     Text format    


  8. LUU T, Kim KP, Blanchard S, Anyang B, et al
    Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Sep 27. doi: 10.1007/s10549-017-4516.
    PubMed     Text format     Abstract available


  9. TSOUTSOU PG, Durham AD, Vozenin MC
    A need for biology-driven personalized radiotherapy in breast cancer.
    Breast Cancer Res Treat. 2017 Sep 27. doi: 10.1007/s10549-017-4522.
    PubMed     Text format    


  10. SAYED S, Moloo Z, Wasike R, Bird P, et al
    Ethnicity and breast cancer characteristics in Kenya.
    Breast Cancer Res Treat. 2017 Sep 26. doi: 10.1007/s10549-017-4511.
    PubMed     Text format     Abstract available


  11. LIU YL, Saraf A, Catanese B, Lee SM, et al
    Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population.
    Breast Cancer Res Treat. 2017 Sep 25. doi: 10.1007/s10549-017-4507.
    PubMed     Text format     Abstract available


  12. CRONIN-FENTON D, Kjaersgaard A, Norgaard M, Amelio J, et al
    Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark.
    Breast Cancer Res Treat. 2017 Sep 25. doi: 10.1007/s10549-017-4510.
    PubMed     Text format     Abstract available


  13. KAUFMAN DI, Shah C, Vicini FA, Rizzi M, et al
    Erratum to: Utilization of bioimpedance spectroscopy in the prevention of chronic breast cancer-related lymphedema.
    Breast Cancer Res Treat. 2017 Sep 20. doi: 10.1007/s10549-017-4505.
    PubMed     Text format     Abstract available


  14. RICE BA, Ver Hoeve ES, DeLuca AN, Esserman LJ, et al
    Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy.
    Breast Cancer Res Treat. 2017 Sep 18. doi: 10.1007/s10549-017-4506.
    PubMed     Text format     Abstract available


  15. JEONG IJ, Lee SG, Kim YH, Ko BS, et al
    Characteristics and prognosis of breast cancer after liver or kidney transplantation.
    Breast Cancer Res Treat. 2017 Sep 15. doi: 10.1007/s10549-017-4504.
    PubMed     Text format     Abstract available


  16. GIANNAKEAS V, Narod SA
    The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy.
    Breast Cancer Res Treat. 2017 Sep 15. doi: 10.1007/s10549-017-4476.
    PubMed     Text format     Abstract available


  17. LEON-FERRE RA, Polley MY, Liu H, Gilbert JA, et al
    Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
    Breast Cancer Res Treat. 2017 Sep 14. doi: 10.1007/s10549-017-4499.
    PubMed     Text format     Abstract available


  18. NYROP KA, Deal AM, Lee JT, Muss HB, et al
    Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?
    Breast Cancer Res Treat. 2017 Sep 14. doi: 10.1007/s10549-017-4501.
    PubMed     Text format     Abstract available


  19. SIEGELMANN-DANIELI N, Katzir I, Landes JV, Segal Y, et al
    Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective.
    Breast Cancer Res Treat. 2017 Sep 14. doi: 10.1007/s10549-017-4491.
    PubMed     Text format     Abstract available


  20. KOCHI M, Iwamoto T, Niikura N, Bianchini G, et al
    Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.
    Breast Cancer Res Treat. 2017 Sep 13. doi: 10.1007/s10549-017-4502.
    PubMed     Text format     Abstract available


  21. MASUNAGA N, Kagara N, Motooka D, Nakamura S, et al
    Highly sensitive detection of ESR1 mutations in cell-free DNA from patients with metastatic breast cancer using molecular barcode sequencing.
    Breast Cancer Res Treat. 2017 Sep 13. doi: 10.1007/s10549-017-4487.
    PubMed     Text format     Abstract available


  22. ROCQUE GB, Williams CP, Jones MI, Kenzik KM, et al
    Healthcare utilization, Medicare spending, and sources of patient distress identified during implementation of a lay navigation program for older patients with breast cancer.
    Breast Cancer Res Treat. 2017 Sep 12. doi: 10.1007/s10549-017-4498.
    PubMed     Text format     Abstract available


  23. NIIKURA N, Shimomura A, Fukatsu Y, Sawaki M, et al
    Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.
    Breast Cancer Res Treat. 2017 Sep 11. doi: 10.1007/s10549-017-4489.
    PubMed     Text format     Abstract available


  24. GREGOROWITSCH ML, van den Bongard HJGD, Young-Afat DA, Pignol JP, et al
    Severe depression more common in patients with ductal carcinoma in situ than early-stage invasive breast cancer patients.
    Breast Cancer Res Treat. 2017 Sep 11. doi: 10.1007/s10549-017-4495.
    PubMed     Text format     Abstract available


  25. SAUNUS JM, Smart CE, Kutasovic JR, Johnston RL, et al
    Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
    Breast Cancer Res Treat. 2017 Sep 9. doi: 10.1007/s10549-017-4496.
    PubMed     Text format     Abstract available


  26. CORTES J, Rugo HS, Awada A, Twelves C, et al
    Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
    Breast Cancer Res Treat. 2017 Sep 7. doi: 10.1007/s10549-017-4482.
    PubMed     Text format    


  27. DREYER MS, Nattinger AB, McGinley EL, Pezzin LE, et al
    Socioeconomic status and breast cancer treatment.
    Breast Cancer Res Treat. 2017 Sep 7. doi: 10.1007/s10549-017-4490.
    PubMed     Text format     Abstract available


  28. THOMAS R, Rowell R, Crichton S, Cain H, et al
    An observational study investigating failure of primary endocrine therapy for operable breast cancer in the elderly.
    Breast Cancer Res Treat. 2017 Sep 6. doi: 10.1007/s10549-017-4494.
    PubMed     Text format     Abstract available


  29. ALTUNDAG K
    Predictive role of loco-regional radiotherapy among metastatic breast cancer patients who had undergone primary tumor surgery.
    Breast Cancer Res Treat. 2017 Sep 5. doi: 10.1007/s10549-017-4493.
    PubMed     Text format    


  30. VAN MACKELENBERGH MT, Denkert C, Nekljudova V, Karn T, et al
    Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.
    Breast Cancer Res Treat. 2017 Sep 5. doi: 10.1007/s10549-017-4480.
    PubMed     Text format     Abstract available


  31. MARTINEZ ME, Gomez SL, Tao L, Cress R, et al
    Erratum to: Contribution of clinical and socioeconomic factors to differences in breast cancer subtype and mortality between Hispanic and non-Hispanic white women.
    Breast Cancer Res Treat. 2017 Sep 4. doi: 10.1007/s10549-017-4455.
    PubMed     Text format    


  32. ALENZI EO, Madhavan SS, Tan X
    Association of the severity of diabetes-related complications with stage of breast cancer at diagnosis among elderly women with pre-existing diabetes.
    Breast Cancer Res Treat. 2017 Sep 2. doi: 10.1007/s10549-017-4477.
    PubMed     Text format     Abstract available


  33. GALLARDO A, Garcia-Valdecasas B, Murata P, Teran R, et al
    Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis.
    Breast Cancer Res Treat. 2017 Sep 1. doi: 10.1007/s10549-017-4486.
    PubMed     Text format     Abstract available


    August 2017
  34. HEITZ AE, Baumgartner RN, Baumgartner KB, Boone SD, et al
    Healthy lifestyle impact on breast cancer-specific and all-cause mortality.
    Breast Cancer Res Treat. 2017 Aug 31. doi: 10.1007/s10549-017-4467.
    PubMed     Text format     Abstract available


  35. VERHEUVEL NC, Voogd AC, Tjan-Heijnen VCG, Siesling S, et al
    Non-visualized sentinel nodes in breast cancer patients; prevalence, risk factors, and prognosis.
    Breast Cancer Res Treat. 2017 Aug 31. doi: 10.1007/s10549-017-4483.
    PubMed     Text format     Abstract available


  36. SUZUKI Y, Tsunoda H, Kimura T, Yamauchi H, et al
    BMI change and abdominal circumference are risk factors for breast cancer, even in Asian women.
    Breast Cancer Res Treat. 2017 Aug 31. doi: 10.1007/s10549-017-4481.
    PubMed     Text format     Abstract available


  37. HAMOOD R, Hamood H, Merhasin I, Keinan-Boker L, et al
    Chronic pain and other symptoms among breast cancer survivors: prevalence, predictors, and effects on quality of life.
    Breast Cancer Res Treat. 2017 Aug 31. doi: 10.1007/s10549-017-4485.
    PubMed     Text format     Abstract available


  38. MALINIAK ML, Patel AV, McCullough ML, Campbell PT, et al
    Obesity, physical activity, and breast cancer survival among older breast cancer survivors in the Cancer Prevention Study-II Nutrition Cohort.
    Breast Cancer Res Treat. 2017 Aug 31. doi: 10.1007/s10549-017-4470.
    PubMed     Text format     Abstract available


  39. AHMED M, Jozsa F, Baker R, Rubio IT, et al
    Erratum to: Meta-analysis of tumour burden in pre-operative axillary ultrasound positive and negative breast cancer patients.
    Breast Cancer Res Treat. 2017 Aug 30. doi: 10.1007/s10549-017-4457.
    PubMed     Text format    


  40. ARCIERO CA, Yang J, Peng L, Ward KC, et al
    African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages.
    Breast Cancer Res Treat. 2017 Aug 30. doi: 10.1007/s10549-017-4484.
    PubMed     Text format     Abstract available


  41. WATANABE J, Hayashi T, Tadokoro Y, Nishimura S, et al
    Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution.
    Breast Cancer Res Treat. 2017 Aug 29. doi: 10.1007/s10549-017-4478.
    PubMed     Text format     Abstract available


  42. DIABY V, Ali AA, Williams KJ, Ezendu K, et al
    Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.
    Breast Cancer Res Treat. 2017 Aug 24. doi: 10.1007/s10549-017-4473.
    PubMed     Text format     Abstract available


  43. LI J, Li H, Makunin I, Thompson BA, et al
    Panel sequencing of 264 candidate susceptibility genes and segregation analysis in a cohort of non-BRCA1, non-BRCA2 breast cancer families.
    Breast Cancer Res Treat. 2017 Aug 24. doi: 10.1007/s10549-017-4469.
    PubMed     Text format     Abstract available


  44. ZHENG G, Yu H, Hemminki A, Forsti A, et al
    Familial associations of male breast cancer with other cancers.
    Breast Cancer Res Treat. 2017 Aug 23. doi: 10.1007/s10549-017-4468.
    PubMed     Text format     Abstract available


  45. REINER AS, Navi BB, DeAngelis LM, Panageas KS, et al
    Increased risk of arterial thromboembolism in older men with breast cancer.
    Breast Cancer Res Treat. 2017 Aug 23. doi: 10.1007/s10549-017-4433.
    PubMed     Text format     Abstract available


  46. HARANO K, Kogawa T, Wu J, Yuan Y, et al
    Thrombocytosis as a prognostic factor in inflammatory breast cancer.
    Breast Cancer Res Treat. 2017 Aug 22. doi: 10.1007/s10549-017-4463.
    PubMed     Text format     Abstract available


  47. RYU JM, Yu J, Kim SI, Kim KS, et al
    Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society.
    Breast Cancer Res Treat. 2017 Aug 22. doi: 10.1007/s10549-017-4472.
    PubMed     Text format     Abstract available


  48. FRISK G, Tinge B, Ekberg S, Eloranta S, et al
    Survival and level of care among breast cancer patients with brain metastases treated with whole brain radiotherapy.
    Breast Cancer Res Treat. 2017 Aug 22. doi: 10.1007/s10549-017-4466.
    PubMed     Text format     Abstract available


  49. KAUFMAN DI, Shah C, Vicini FA, Rizzi M, et al
    Utilization of bioimpedance spectroscopy in the prevention of chronic breast cancer-related lymphedema.
    Breast Cancer Res Treat. 2017 Aug 22. doi: 10.1007/s10549-017-4451.
    PubMed     Text format     Abstract available


  50. HACK CC, Emons J, Jud SM, Heusinger K, et al
    Association between mammographic density and pregnancies relative to age and BMI: a breast cancer case-only analysis.
    Breast Cancer Res Treat. 2017 Aug 21. doi: 10.1007/s10549-017-4446.
    PubMed     Text format     Abstract available


  51. NARAYAN A, Lebron-Zapata L, Morris E
    Breast cancer screening in transgender patients: findings from the 2014 BRFSS survey.
    Breast Cancer Res Treat. 2017 Aug 21. doi: 10.1007/s10549-017-4461.
    PubMed     Text format     Abstract available


  52. HOPKINS JO, Allred J, Hurria A, Jatoi A, et al
    Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302).
    Breast Cancer Res Treat. 2017 Aug 20. doi: 10.1007/s10549-017-4454.
    PubMed     Text format     Abstract available


  53. ZHANG K, Zhou J, Zhu X, Luo M, et al
    Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer.
    Breast Cancer Res Treat. 2017 Aug 20. doi: 10.1007/s10549-017-4425.
    PubMed     Text format     Abstract available


  54. HILL DA, Barry M, Wiggins C, Nibbe A, et al
    Estrogen receptor quantitative measures and breast cancer survival.
    Breast Cancer Res Treat. 2017 Aug 19. doi: 10.1007/s10549-017-4439.
    PubMed     Text format     Abstract available


  55. CHOI HD, Chang MJ
    Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis.
    Breast Cancer Res Treat. 2017 Aug 19. doi: 10.1007/s10549-017-4460.
    PubMed     Text format     Abstract available


  56. DONG Y, Li T, Churilla TM, Shaikh T, et al
    Impact of rheumatoid arthritis on radiation-related toxicity and cosmesis in breast cancer patients: a contemporary matched-pair analysis.
    Breast Cancer Res Treat. 2017 Aug 19. doi: 10.1007/s10549-017-4438.
    PubMed     Text format     Abstract available


  57. JACKLYN G, McGeechan K, Irwig L, Houssami N, et al
    Trends in stage-specific breast cancer incidence in New South Wales, Australia: insights into the effects of 25 years of screening mammography.
    Breast Cancer Res Treat. 2017 Aug 19. doi: 10.1007/s10549-017-4443.
    PubMed     Text format     Abstract available


  58. BONOFIGLIO D, Gabriele S, Aquila S, Qi H, et al
    Erratum to: Peroxisome proliferator-activated receptor gamma activates fas ligand gene promoter inducing apoptosis in human breast cancer cells.
    Breast Cancer Res Treat. 2017 Aug 18. doi: 10.1007/s10549-017-4456.
    PubMed     Text format    


  59. JAKABOVA A, Bielcikova Z, Pospisilova E, Matkowski R, et al
    Molecular characterization and heterogeneity of circulating tumor cells in breast cancer.
    Breast Cancer Res Treat. 2017 Aug 16. doi: 10.1007/s10549-017-4452.
    PubMed     Text format     Abstract available


  60. NATHAN S, Ma Y, Tomita YA, De Oliveira E, et al
    BRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-alpha occupancy in the IKKB promoter and inhibits NF-kappaB activity in antiestrogen-resistant human breast cancer cells.
    Breast Cancer Res Treat. 2017 Aug 14. doi: 10.1007/s10549-017-4442.
    PubMed     Text format     Abstract available


  61. NEIL-SZTRAMKO SE, Boyle T, Milosevic E, Nugent SF, et al
    Does obesity modify the relationship between physical activity and breast cancer risk?
    Breast Cancer Res Treat. 2017 Aug 12. doi: 10.1007/s10549-017-4449.
    PubMed     Text format     Abstract available


  62. LODI M, Scheer L, Reix N, Heitz D, et al
    Breast cancer in elderly women and altered clinico-pathological characteristics: a systematic review.
    Breast Cancer Res Treat. 2017 Aug 12. doi: 10.1007/s10549-017-4448.
    PubMed     Text format     Abstract available


  63. BLAES A, Beckwith H, Florea N, Hebbel R, et al
    Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study.
    Breast Cancer Res Treat. 2017 Aug 11. doi: 10.1007/s10549-017-4447.
    PubMed     Text format     Abstract available


  64. WINHAM SJ, Mehner C, Heinzen EP, Broderick BT, et al
    NanoString-based breast cancer risk prediction for women with sclerosing adenosis.
    Breast Cancer Res Treat. 2017 Aug 10. doi: 10.1007/s10549-017-4441.
    PubMed     Text format     Abstract available


  65. PALMIERI C, Szydlo R, Miller M, Barker L, et al
    IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer.
    Breast Cancer Res Treat. 2017 Aug 9. doi: 10.1007/s10549-017-4427.
    PubMed     Text format     Abstract available


  66. MUSTAFA ALI M, Moeller M, Rybicki L, Moore HCF, et al
    Long-term peripheral neuropathy symptoms in breast cancer survivors.
    Breast Cancer Res Treat. 2017 Aug 8. doi: 10.1007/s10549-017-4437.
    PubMed     Text format     Abstract available


  67. SHIEH Y, Hu D, Ma L, Huntsman S, et al
    Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones.
    Breast Cancer Res Treat. 2017 Aug 8. doi: 10.1007/s10549-017-4430.
    PubMed     Text format     Abstract available


  68. WISE R, Zolkiewska A
    Metalloprotease-dependent activation of EGFR modulates CD44+/CD24- populations in triple negative breast cancer cells through the MEK/ERK pathway.
    Breast Cancer Res Treat. 2017 Aug 8. doi: 10.1007/s10549-017-4440.
    PubMed     Text format     Abstract available


  69. HEALEY MA, Hirko KA, Beck AH, Collins LC, et al
    Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses' Health Study.
    Breast Cancer Res Treat. 2017 Aug 8. doi: 10.1007/s10549-017-4421.
    PubMed     Text format     Abstract available


  70. JOO JH, Kim SS, Ahn SD, Choi EK, et al
    Impact of pathologic diagnosis of internal mammary lymph node metastasis in clinical N2b and N3b breast cancer patients.
    Breast Cancer Res Treat. 2017 Aug 7. doi: 10.1007/s10549-017-4422.
    PubMed     Text format     Abstract available


  71. SPEYER CL, Bukhsh MA, Jafry WS, Sexton RE, et al
    Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
    Breast Cancer Res Treat. 2017 Aug 5. doi: 10.1007/s10549-017-4435.
    PubMed     Text format     Abstract available


  72. CORSINI C, Henouda S, Nejima DB, Bertet H, et al
    Early onset breast cancer: differences in risk factors, tumor phenotype, and genotype between North African and South European women.
    Breast Cancer Res Treat. 2017 Aug 5. doi: 10.1007/s10549-017-4434.
    PubMed     Text format     Abstract available


  73. LUKONG KE, Ogunbolude Y, Kamdem JP
    Breast cancer in Africa: prevalence, treatment options, herbal medicines, and socioeconomic determinants.
    Breast Cancer Res Treat. 2017 Aug 4. doi: 10.1007/s10549-017-4408.
    PubMed     Text format     Abstract available


  74. KHAN QJ, Kimler BF, Reddy PS, Sharma P, et al
    Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial.
    Breast Cancer Res Treat. 2017 Aug 2. doi: 10.1007/s10549-017-4429.
    PubMed     Text format     Abstract available


  75. ZHENG K, Tan JX, Li F, Wei YX, et al
    Relationship between mammographic calcifications and the clinicopathologic characteristics of breast cancer in Western China: a retrospective multi-center study of 7317 female patients.
    Breast Cancer Res Treat. 2017 Aug 2. doi: 10.1007/s10549-017-4406.
    PubMed     Text format     Abstract available


  76. ALKNER S, Jensen MB, Rasmussen BB, Bendahl PO, et al
    Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.
    Breast Cancer Res Treat. 2017 Aug 1. doi: 10.1007/s10549-017-4416.
    PubMed     Text format     Abstract available


  77. KANG YJ, Han W, Park S, You JY, et al
    Outcome following sentinel lymph node biopsy-guided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2017 Aug 1. doi: 10.1007/s10549-017-4423.
    PubMed     Text format     Abstract available


    July 2017
  78. FISCHER MJ, Inoue K, Matsuda A, Kroep JR, et al
    Cross-cultural comparison of breast cancer patients' Quality of Life in the Netherlands and Japan.
    Breast Cancer Res Treat. 2017 Jul 31. doi: 10.1007/s10549-017-4417.
    PubMed     Text format     Abstract available


  79. GEOFFROY M, Kleinclauss A, Grandemange S, Hupont S, et al
    Erratum to: Pro-apoptotic effect of Delta2-TGZ in "claudin-1-low" triple-negative breast cancer cells: involvement of claudin-1.
    Breast Cancer Res Treat. 2017 Jul 31. doi: 10.1007/s10549-017-4402.
    PubMed     Text format    


  80. PETRELLI F, Tomasello G, Barni S, Lonati V, et al
    Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature.
    Breast Cancer Res Treat. 2017 Jul 31. doi: 10.1007/s10549-017-4419.
    PubMed     Text format     Abstract available


  81. MORENO AYALA MA, Gottardo MF, Imsen M, Asad AS, et al
    Therapeutic blockade of Foxp3 in experimental breast cancer models.
    Breast Cancer Res Treat. 2017 Jul 29. doi: 10.1007/s10549-017-4414.
    PubMed     Text format     Abstract available


  82. ESPINAL AC, Buas MF, Wang D, Cheng DT, et al
    FOXA1 hypermethylation: link between parity and ER-negative breast cancer in African American women?
    Breast Cancer Res Treat. 2017 Jul 29. doi: 10.1007/s10549-017-4418.
    PubMed     Text format     Abstract available


  83. AHMED M, Jozsa F, Baker R, Rubio IT, et al
    Meta-analysis of tumour burden in pre-operative axillary ultrasound positive and negative breast cancer patients.
    Breast Cancer Res Treat. 2017 Jul 28. doi: 10.1007/s10549-017-4405.
    PubMed     Text format     Abstract available


  84. SANTA-MARIA CA, Kruse M, Raska P, Weiss M, et al
    Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers.
    Breast Cancer Res Treat. 2017 Jul 27. doi: 10.1007/s10549-017-4415.
    PubMed     Text format     Abstract available


  85. ACCORDINO MK, Wright JD, Vasan S, Neugut AI, et al
    Association between survival time with metastatic breast cancer and aggressive end-of-life care.
    Breast Cancer Res Treat. 2017 Jul 27. doi: 10.1007/s10549-017-4420.
    PubMed     Text format     Abstract available


  86. WILSON FR, Varu A, Mitra D, Cameron C, et al
    Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Jul 27. doi: 10.1007/s10549-017-4404.
    PubMed     Text format     Abstract available


  87. LUITEN JD, Voogd AC, Luiten EJT, Duijm LEM, et al
    Trends in incidence and tumour grade in screen-detected ductal carcinoma in situ and invasive breast cancer.
    Breast Cancer Res Treat. 2017 Jul 26. doi: 10.1007/s10549-017-4412.
    PubMed     Text format     Abstract available


  88. WATT LF, Panicker N, Mannan A, Copeland B, et al
    Functional importance of PP2A regulatory subunit loss in breast cancer.
    Breast Cancer Res Treat. 2017 Jul 25. doi: 10.1007/s10549-017-4403.
    PubMed     Text format     Abstract available


  89. GROBMYER SR, Djohan R
    Comments on "Primary tumor location predicts the site of local relapse after nipple-areola complex (NAC) sparing mastectomy" by Cont et al. Breast Cancer Res Treat, 2017.
    Breast Cancer Res Treat. 2017 Jul 25. doi: 10.1007/s10549-017-4409.
    PubMed     Text format    


  90. SHI M, Ma F, Liu J, Xing H, et al
    A functional BRCA1 coding sequence genetic variant contributes to prognosis of triple-negative breast cancer, especially after radiotherapy.
    Breast Cancer Res Treat. 2017 Jul 25. doi: 10.1007/s10549-017-4395.
    PubMed     Text format     Abstract available


  91. WU W, Chen J, Ye W, Li X, et al
    Fatty liver decreases the risk of liver metastasis in patients with breast cancer: a two-center cohort study.
    Breast Cancer Res Treat. 2017 Jul 24. doi: 10.1007/s10549-017-4411.
    PubMed     Text format     Abstract available


  92. KWAPISZ D
    Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Breast Cancer Res Treat. 2017 Jul 24. doi: 10.1007/s10549-017-4385.
    PubMed     Text format     Abstract available


  93. HERTZ DL, Kidwell KM, Hilsenbeck SG, Oesterreich S, et al
    CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.
    Breast Cancer Res Treat. 2017 Jul 20. doi: 10.1007/s10549-017-4400.
    PubMed     Text format     Abstract available


  94. SANTIAGO L, Adrada BE, Huang ML, Wei W, et al
    Breast cancer neoplastic seeding in the setting of image-guided needle biopsies of the breast.
    Breast Cancer Res Treat. 2017 Jul 20. doi: 10.1007/s10549-017-4401.
    PubMed     Text format     Abstract available


  95. LIU H, Wang J, Zhang M, Xuan Q, et al
    Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients.
    Breast Cancer Res Treat. 2017 Jul 20. doi: 10.1007/s10549-017-4394.
    PubMed     Text format     Abstract available


  96. IGLAY K, Santorelli ML, Hirshfield KM, Williams JM, et al
    Diagnosis and treatment delays among elderly breast cancer patients with pre-existing mental illness.
    Breast Cancer Res Treat. 2017 Jul 19. doi: 10.1007/s10549-017-4399.
    PubMed     Text format     Abstract available


  97. GONZALEZ-RIVERA M, Lobo M, Lopez-Tarruella S, Jerez Y, et al
    Erratum to: Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.
    Breast Cancer Res Treat. 2017 Jul 18. doi: 10.1007/s10549-017-4396.
    PubMed     Text format    


  98. SCHOORMANS D, van de Poll-Franse L, Vissers P, van Herk-Sukel MPP, et al
    Pharmaceutically treated anxiety but not depression prior to cancer diagnosis predicts the onset of cardiovascular disease among breast cancer survivors.
    Breast Cancer Res Treat. 2017 Jul 17. doi: 10.1007/s10549-017-4387.
    PubMed     Text format     Abstract available


  99. CHANG JS, Ko BK, Bae JW, Yu JH, et al
    Radiation-related heart disease after breast cancer radiation therapy in Korean women.
    Breast Cancer Res Treat. 2017 Jul 17. doi: 10.1007/s10549-017-4398.
    PubMed     Text format     Abstract available


  100. MILLER P, Kidwell KM, Thomas D, Sabel M, et al
    Elevated S100A8 protein expression in breast cancer cells and breast tumor stroma is prognostic of poor disease outcome.
    Breast Cancer Res Treat. 2017 Jul 17. doi: 10.1007/s10549-017-4366.
    PubMed     Text format     Abstract available


  101. GUO L, Yuan P, Zhang J, Ling Y, et al
    Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer.
    Breast Cancer Res Treat. 2017 Jul 15. doi: 10.1007/s10549-017-4397.
    PubMed     Text format     Abstract available


  102. YU AF, Mukku RB, Verma S, Liu JE, et al
    Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Breast Cancer Res Treat. 2017 Jul 14. doi: 10.1007/s10549-017-4362.
    PubMed     Text format     Abstract available


  103. VAN DYK K, Hunter AM, Ercoli L, Petersen L, et al
    Evaluating cognitive complaints in breast cancer survivors with the FACT-Cog and quantitative electroencephalography.
    Breast Cancer Res Treat. 2017 Jul 13. doi: 10.1007/s10549-017-4390.
    PubMed     Text format     Abstract available


  104. YAO C, Bernstein LJ, Rich JB
    Executive functioning impairment in women treated with chemotherapy for breast cancer: a systematic review.
    Breast Cancer Res Treat. 2017 Jul 13. doi: 10.1007/s10549-017-4376.
    PubMed     Text format     Abstract available


  105. NJOROGE SW, Burgess KR, Cobleigh MA, Alnajar HH, et al
    Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient.
    Breast Cancer Res Treat. 2017 Jul 12. doi: 10.1007/s10549-017-4393.
    PubMed     Text format     Abstract available


  106. RICE MS, Tworoger SS, Hankinson SE, Tamimi RM, et al
    Breast cancer risk prediction: an update to the Rosner-Colditz breast cancer incidence model.
    Breast Cancer Res Treat. 2017 Jul 12. doi: 10.1007/s10549-017-4391.
    PubMed     Text format     Abstract available


  107. KIISKI JI, Tervasmaki A, Pelttari LM, Khan S, et al
    FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population.
    Breast Cancer Res Treat. 2017 Jul 12. doi: 10.1007/s10549-017-4388.
    PubMed     Text format     Abstract available


  108. TURASHVILI G, Chou JF, Brogi E, Morrow M, et al
    21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2017 Jul 12. doi: 10.1007/s10549-017-4381.
    PubMed     Text format     Abstract available


  109. TROGDON JG, Ekwueme DU, Poehler D, Thomas CC, et al
    Medical costs of treating breast cancer among younger medicaid beneficiaries by stage at diagnosis.
    Breast Cancer Res Treat. 2017 Jul 12. doi: 10.1007/s10549-017-4386.
    PubMed     Text format     Abstract available


  110. CHIHARA Y, Shimoda M, Hori A, Ohara A, et al
    A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
    Breast Cancer Res Treat. 2017 Jul 12. doi: 10.1007/s10549-017-4382.
    PubMed     Text format     Abstract available


  111. HEGDE JV, Wang X, Attai DJ, DiNome ML, et al
    Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer.
    Breast Cancer Res Treat. 2017 Jul 12. doi: 10.1007/s10549-017-4392.
    PubMed     Text format     Abstract available


  112. MARTINEZ ME, Gomez SL, Tao L, Cress R, et al
    Contribution of clinical and socioeconomic factors to differences in breast cancer subtype and mortality between Hispanic and non-Hispanic white women.
    Breast Cancer Res Treat. 2017 Jul 11. doi: 10.1007/s10549-017-4389.
    PubMed     Text format     Abstract available


  113. VOGL SE
    Adjuvant ovarian suppression for resected breast cancer: 2017 critical assessment.
    Breast Cancer Res Treat. 2017 Jul 10. doi: 10.1007/s10549-017-4379.
    PubMed     Text format     Abstract available


  114. HILLIARD C
    Letter to the editor: In response to "influence of clinical, societal, and treatment variables on racial difference in ER-/PR- breast cancer survival" by Roseland ME, Schwartz K, Ruterbusch JJ, Lamerato L, Krajenta R, Booza J, Simon MS.
    Breast Cancer Res Treat. 2017 Jul 10. doi: 10.1007/s10549-017-4360.
    PubMed     Text format    


  115. KATZ SJ, Hawley ST, Bondarenko I, Jagsi R, et al
    Oncologists' influence on receipt of adjuvant chemotherapy: does it matter whom you see for treatment of curable breast cancer?
    Breast Cancer Res Treat. 2017 Jul 8. doi: 10.1007/s10549-017-4377.
    PubMed     Text format     Abstract available


  116. PARISE CA, Caggiano V
    Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors.
    Breast Cancer Res Treat. 2017 Jul 8. doi: 10.1007/s10549-017-4383.
    PubMed     Text format     Abstract available


  117. LEYRER CM, Berriochoa CA, Agrawal S, Donaldson A, et al
    Predictive factors on outcomes in metaplastic breast cancer.
    Breast Cancer Res Treat. 2017 Jul 8. doi: 10.1007/s10549-017-4367.
    PubMed     Text format     Abstract available


  118. POUWELS XGLV, Ramaekers BLT, Joore MA
    Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Jul 8. doi: 10.1007/s10549-017-4374.
    PubMed     Text format     Abstract available


  119. MU Z, Wang C, Ye Z, Rossi G, et al
    Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Jul 7. doi: 10.1007/s10549-017-4372.
    PubMed     Text format     Abstract available


  120. MARINE G, Alexandra K, Stephanie G, Sebastien H, et al
    Pro-apoptotic effect of Delta2-TGZ in "claudin-1-low" triple-negative breast cancer cells: involvement of claudin-1.
    Breast Cancer Res Treat. 2017 Jul 5. doi: 10.1007/s10549-017-4378.
    PubMed     Text format     Abstract available


  121. BUNDRED NJ, Thomas J, Dixon JMJ
    Whither surgical quality assurance of breast cancer surgery (surgical margins and local recurrence) after paterson.
    Breast Cancer Res Treat. 2017 Jul 5. doi: 10.1007/s10549-017-4369.
    PubMed     Text format     Abstract available


  122. RUGO HS, Tredan O, Ro J, Morales SM, et al
    A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.
    Breast Cancer Res Treat. 2017 Jul 5. doi: 10.1007/s10549-017-4375.
    PubMed     Text format     Abstract available


  123. HURTZ HJ, Tesch H, Gohler T, Hutzschenreuter U, et al
    Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer: results from the MaTox project.
    Breast Cancer Res Treat. 2017 Jul 5. doi: 10.1007/s10549-017-4365.
    PubMed     Text format     Abstract available


  124. GEURTS YM, Witteveen A, Bretveld R, Poortmans PM, et al
    Patterns and predictors of first and subsequent recurrence in women with early breast cancer.
    Breast Cancer Res Treat. 2017 Jul 4. doi: 10.1007/s10549-017-4340.
    PubMed     Text format     Abstract available


  125. EHLERS DK, Aguinaga S, Cosman J, Severson J, et al
    The effects of physical activity and fatigue on cognitive performance in breast cancer survivors.
    Breast Cancer Res Treat. 2017 Jul 4. doi: 10.1007/s10549-017-4363.
    PubMed     Text format     Abstract available


  126. VRIENS BEPJ, Vriens IJH, Aarts MJB, van Gastel SM, et al
    Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Jul 3. doi: 10.1007/s10549-017-4364.
    PubMed     Text format     Abstract available


  127. COSTA R, Santa-Maria CA, Scholtens DM, Jain S, et al
    A pilot study of cabergoline for the treatment of metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Jul 3. doi: 10.1007/s10549-017-4370.
    PubMed     Text format     Abstract available


  128. ROSSO KJ, Ueno NT, Woodward WA, Lucci A, et al
    In response to "outcomes of patients with inflammatory breast cancer treated by breast conserving surgery": the argument against breast conservation and sentinel lymph node biopsy in IBC.
    Breast Cancer Res Treat. 2017 Jul 3. doi: 10.1007/s10549-017-4337.
    PubMed     Text format    


    June 2017
  129. ABDEL-RAZEQ H, Marei L, Saadeh SS, Abdulelah H, et al
    From clinical trials to clinical practice: outcome of NSABP-B27 neoadjuvant chemotherapy regimen for high-risk early-stage breast cancer.
    Breast Cancer Res Treat. 2017 Jun 30. doi: 10.1007/s10549-017-4359.
    PubMed     Text format     Abstract available


  130. NITZ U, Gluz O, Christgen M, Kates RE, et al
    Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
    Breast Cancer Res Treat. 2017 Jun 29. doi: 10.1007/s10549-017-4358.
    PubMed     Text format     Abstract available


  131. YANG XR, Devi BCR, Sung H, Guida J, et al
    Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
    Breast Cancer Res Treat. 2017 Jun 29. doi: 10.1007/s10549-017-4356.
    PubMed     Text format     Abstract available


  132. CHIEN AJ, Chambers J, Mcauley F, Kaplan T, et al
    Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.
    Breast Cancer Res Treat. 2017 Jun 28. doi: 10.1007/s10549-017-4350.
    PubMed     Text format    


  133. VERHEUVEL NC, Voogd AC, Tjan-Heijnen VCG, Siesling S, et al
    Different outcome in node-positive breast cancer patients found by axillary ultrasound or sentinel node procedure.
    Breast Cancer Res Treat. 2017 Jun 27. doi: 10.1007/s10549-017-4342.
    PubMed     Text format     Abstract available


  134. BLUETHMANN SM, Alfano CM, Clapp JD, Luta G, et al
    Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance).
    Breast Cancer Res Treat. 2017 Jun 26. doi: 10.1007/s10549-017-4353.
    PubMed     Text format     Abstract available


  135. MAXWELL KN, Soucier-Ernst D, Tahirovic E, Troxel AB, et al
    Erratum to: Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Jun 26. doi: 10.1007/s10549-017-4339.
    PubMed     Text format    


  136. PARTRIDGE AH, Sepucha K, O'Neill A, Miller KD, et al
    Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy?
    Breast Cancer Res Treat. 2017 Jun 23. doi: 10.1007/s10549-017-4338.
    PubMed     Text format     Abstract available


  137. HERTZ DL, Speth KA, Kidwell KM, Gersch CL, et al
    Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients.
    Breast Cancer Res Treat. 2017 Jun 22. doi: 10.1007/s10549-017-4346.
    PubMed     Text format     Abstract available


  138. ELEBRO K, Bendahl PO, Jernstrom H, Borgquist S, et al
    Androgen receptor expression and breast cancer mortality in a population-based prospective cohort.
    Breast Cancer Res Treat. 2017 Jun 22. doi: 10.1007/s10549-017-4343.
    PubMed     Text format     Abstract available


  139. THISTLE JE, Hellberg Y, Mortensen K, Hamilton-Dutoit S, et al
    The effect of 14-3-3zeta expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.
    Breast Cancer Res Treat. 2017 Jun 22. doi: 10.1007/s10549-017-4289.
    PubMed     Text format     Abstract available


  140. ARTHUR R, Wang Y, Ye K, Glass AG, et al
    Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease.
    Breast Cancer Res Treat. 2017 Jun 22. doi: 10.1007/s10549-017-4347.
    PubMed     Text format     Abstract available


  141. ASKOXYLAKIS V, Kodack DP, Ferraro GB, Jain RK, et al
    Antibody-based therapies for the treatment of brain metastases from HER2-positive breast cancer: time to rethink the importance of the BBB?
    Breast Cancer Res Treat. 2017 Jun 22. doi: 10.1007/s10549-017-4351.
    PubMed     Text format    


  142. TAN X, Camacho TF, LeBaron VT, Blackhall LJ, et al
    Opioid use among female breast cancer patients using different adjuvant endocrine therapy regimens.
    Breast Cancer Res Treat. 2017 Jun 21. doi: 10.1007/s10549-017-4348.
    PubMed     Text format     Abstract available


  143. CLARK BL, Murphy MA, Kamdem LK
    COX2 induction: a mechanism of endocrine breast cancer resistance?
    Breast Cancer Res Treat. 2017 Jun 21. doi: 10.1007/s10549-017-4284.
    PubMed     Text format     Abstract available


  144. CINTOLO-GONZALEZ JA, Braun D, Blackford AL, Mazzola E, et al
    Erratum to: Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications.
    Breast Cancer Res Treat. 2017 Jun 21. doi: 10.1007/s10549-017-4349.
    PubMed     Text format    


  145. LIEDE A, Mansfield CA, Metcalfe KA, Price MA, et al
    Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment.
    Breast Cancer Res Treat. 2017 Jun 17. doi: 10.1007/s10549-017-4332.
    PubMed     Text format     Abstract available


  146. YAGHJYAN L, Tamimi RM, Bertrand KA, Scott CG, et al
    Interaction of mammographic breast density with menopausal status and postmenopausal hormone use in relation to the risk of aggressive breast cancer subtypes.
    Breast Cancer Res Treat. 2017 Jun 17. doi: 10.1007/s10549-017-4341.
    PubMed     Text format     Abstract available


  147. GOLDSTEIN LJ, Zhao F, Wang M, Swaby RF, et al
    A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Gro
    Breast Cancer Res Treat. 2017 Jun 16. doi: 10.1007/s10549-017-4310.
    PubMed     Text format     Abstract available


  148. VERNIERI C, Milano M, Mennitto A, Maggi C, et al
    Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study.
    Breast Cancer Res Treat. 2017 Jun 14. doi: 10.1007/s10549-017-4336.
    PubMed     Text format     Abstract available


  149. GONCALVES R, DeSchryver K, Ma C, Tao Y, et al
    Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer.
    Breast Cancer Res Treat. 2017 Jun 13. doi: 10.1007/s10549-017-4329.
    PubMed     Text format     Abstract available


  150. PALMIERI C, Stein RC, Liu X, Hudson E, et al
    IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
    Breast Cancer Res Treat. 2017 Jun 13. doi: 10.1007/s10549-017-4328.
    PubMed     Text format     Abstract available


  151. CORTES J, Rugo HS, Awada A, Twelves C, et al
    Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
    Breast Cancer Res Treat. 2017 Jun 13. doi: 10.1007/s10549-017-4304.
    PubMed     Text format     Abstract available


  152. WINTERS H, Tielemans HJP, Hameeteman M, Paulus VAA, et al
    The efficacy of lymphaticovenular anastomosis in breast cancer-related lymphedema.
    Breast Cancer Res Treat. 2017 Jun 12. doi: 10.1007/s10549-017-4335.
    PubMed     Text format     Abstract available


  153. YOON TI, Hwang UK, Kim ET, Lee S, et al
    Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy.
    Breast Cancer Res Treat. 2017 Jun 10. doi: 10.1007/s10549-017-4331.
    PubMed     Text format     Abstract available


  154. SOPIK V, Sun P, Narod SA
    The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients.
    Breast Cancer Res Treat. 2017 Jun 10. doi: 10.1007/s10549-017-4333.
    PubMed     Text format     Abstract available


  155. GLYNN RJ, Colditz GA, Tamimi RM, Chen WY, et al
    Extensions of the Rosner-Colditz breast cancer prediction model to include older women and type-specific predicted risk.
    Breast Cancer Res Treat. 2017 Jun 6. doi: 10.1007/s10549-017-4319.
    PubMed     Text format     Abstract available


  156. SHI J, Kobayashi LC, Grundy A, Richardson H, et al
    Lifetime moderate-to-vigorous physical activity and ER/PR/HER-defined post-menopausal breast cancer risk.
    Breast Cancer Res Treat. 2017 Jun 6. doi: 10.1007/s10549-017-4323.
    PubMed     Text format     Abstract available


  157. HOUSSAMI N, Turner RM, Morrow M
    Meta-analysis of pre-operative magnetic resonance imaging (MRI) and surgical treatment for breast cancer.
    Breast Cancer Res Treat. 2017 Jun 6. doi: 10.1007/s10549-017-4324.
    PubMed     Text format     Abstract available


  158. HEIMES AS, Madjar K, Edlund K, Battista MJ, et al
    Subtype-specific prognostic impact of different immune signatures in node-negative breast cancer.
    Breast Cancer Res Treat. 2017 Jun 5. doi: 10.1007/s10549-017-4327.
    PubMed     Text format     Abstract available


  159. TAKANEN S, Gambirasio A, Gritti G, Kalli M, et al
    Breast cancer electron intraoperative radiotherapy: assessment of preoperative selection factors from a retrospective analysis of 758 patients and review of literature.
    Breast Cancer Res Treat. 2017 Jun 3. doi: 10.1007/s10549-017-4321.
    PubMed     Text format     Abstract available


  160. BREWER HR, Jones ME, Schoemaker MJ, Ashworth A, et al
    Family history and risk of breast cancer: an analysis accounting for family structure.
    Breast Cancer Res Treat. 2017 Jun 3. doi: 10.1007/s10549-017-4325.
    PubMed     Text format     Abstract available


  161. TURASHVILI G, Brogi E, Morrow M, Hudis C, et al
    The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.
    Breast Cancer Res Treat. 2017 Jun 3. doi: 10.1007/s10549-017-4326.
    PubMed     Text format     Abstract available


  162. VIDULA N, Yau C, Li J, Esserman LJ, et al
    Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).
    Breast Cancer Res Treat. 2017 Jun 2. doi: 10.1007/s10549-017-4318.
    PubMed     Text format     Abstract available


  163. KANG JW, Shin HJ, Shin KC, Chae EY, et al
    Unenhanced magnetic resonance screening using fused diffusion-weighted imaging and maximum-intensity projection in patients with a personal history of breast cancer: role of fused DWI for postoperative screening.
    Breast Cancer Res Treat. 2017 Jun 2. doi: 10.1007/s10549-017-4322.
    PubMed     Text format     Abstract available


  164. CAMPBELL JI, Yau C, Krass P, Moore D, et al
    Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Breast Cancer Res Treat. 2017 Jun 2. doi: 10.1007/s10549-017-4303.
    PubMed     Text format     Abstract available


  165. LIN C, Clark R, Tu P, Bosworth HB, et al
    Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers.
    Breast Cancer Res Treat. 2017 Jun 1. doi: 10.1007/s10549-017-4317.
    PubMed     Text format     Abstract available


  166. YOO TK, Chae BJ, Kim SJ, Lee J, et al
    Identifying long-term survivors among metastatic breast cancer patients undergoing primary tumor surgery.
    Breast Cancer Res Treat. 2017 Jun 1. doi: 10.1007/s10549-017-4309.
    PubMed     Text format     Abstract available


    May 2017
  167. FLISTER MJ, Tsaih SW, Stoddard A, Plasterer C, et al
    Host genetic modifiers of nonproductive angiogenesis inhibit breast cancer.
    Breast Cancer Res Treat. 2017 May 31. doi: 10.1007/s10549-017-4311.
    PubMed     Text format     Abstract available


  168. JUTAGIR DR, Blomberg BB, Carver CS, Lechner SC, et al
    Social well-being is associated with less pro-inflammatory and pro-metastatic leukocyte gene expression in women after surgery for breast cancer.
    Breast Cancer Res Treat. 2017 May 30. doi: 10.1007/s10549-017-4316.
    PubMed     Text format     Abstract available


  169. THOMSON CA, Chow HHS, Wertheim BC, Roe DJ, et al
    A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen.
    Breast Cancer Res Treat. 2017 May 30. doi: 10.1007/s10549-017-4292.
    PubMed     Text format     Abstract available


  170. SYROWATKA A, Motulsky A, Kurteva S, Hanley JA, et al
    Predictors of distress in female breast cancer survivors: a systematic review.
    Breast Cancer Res Treat. 2017 May 28. doi: 10.1007/s10549-017-4290.
    PubMed     Text format     Abstract available


  171. BOURKE M, Soden D, Clover AJP
    Erratum to: Effective treatment of intractable cutaneous metastases of breast cancer with electrochemotherapy: a useful contributor to cutaneous disease control.
    Breast Cancer Res Treat. 2017 May 27. doi: 10.1007/s10549-017-4307.
    PubMed     Text format    


  172. FAN C, Georgiou KR, Morris HA, McKinnon RA, et al
    Combination breast cancer chemotherapy with doxorubicin and cyclophosphamide damages bone and bone marrow in a female rat model.
    Breast Cancer Res Treat. 2017 May 26. doi: 10.1007/s10549-017-4308.
    PubMed     Text format     Abstract available


  173. ROSELAND ME, Schwartz K, Ruterbusch JJ, Lamerato L, et al
    Influence of clinical, societal, and treatment variables on racial differences in ER-/PR- breast cancer survival.
    Breast Cancer Res Treat. 2017 May 25. doi: 10.1007/s10549-017-4300.
    PubMed     Text format     Abstract available


  174. ELLEGAARD MB, Grau C, Zachariae R, Jensen AB, et al
    Women with breast cancer report substantially more disease- and treatment-related side or late effects than registered by clinical oncologists: a cross-sectional study of a standard follow-up program in an oncological department.
    Breast Cancer Res Treat. 2017 May 23. doi: 10.1007/s10549-017-4301.
    PubMed     Text format     Abstract available


  175. KELKAR MG, Thakur B, Derle A, Chatterjee S, et al
    Tumor suppressor protein p53 exerts negative transcriptional regulation on human sodium iodide symporter gene expression in breast cancer.
    Breast Cancer Res Treat. 2017 May 20. doi: 10.1007/s10549-017-4297.
    PubMed     Text format     Abstract available


  176. EDWARDS MJ, Campbell ID, Lawrenson RA, Kuper-Hommel MJ, et al
    Influence of comorbidity on chemotherapy use for early breast cancer: systematic review and meta-analysis.
    Breast Cancer Res Treat. 2017 May 20. doi: 10.1007/s10549-017-4295.
    PubMed     Text format     Abstract available


  177. KOPANS DB
    The Canadian National Breast Screening Studies are compromised and their results are unreliable. They should not factor into decisions about breast cancer screening.
    Breast Cancer Res Treat. 2017 May 20. doi: 10.1007/s10549-017-4302.
    PubMed     Text format     Abstract available


  178. GOBEL A, Kuhlmann JD, Link T, Wimberger P, et al
    Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.
    Breast Cancer Res Treat. 2017 May 19. doi: 10.1007/s10549-017-4296.
    PubMed     Text format     Abstract available


  179. RAFFERTY EA, Rose SL, Miller DP, Durand MA, et al
    Effect of age on breast cancer screening using tomosynthesis in combination with digital mammography.
    Breast Cancer Res Treat. 2017 May 18. doi: 10.1007/s10549-017-4299.
    PubMed     Text format     Abstract available


  180. YUN SJ, Ryu CW, Rhee SJ, Ryu JK, et al
    Benefit of adding digital breast tomosynthesis to digital mammography for breast cancer screening focused on cancer characteristics: a meta-analysis.
    Breast Cancer Res Treat. 2017 May 18. doi: 10.1007/s10549-017-4298.
    PubMed     Text format     Abstract available


  181. YARDLEY DA, Arrowsmith ER, Daniel BR, Eakle J, et al
    TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.
    Breast Cancer Res Treat. 2017 May 15. doi: 10.1007/s10549-017-4285.
    PubMed     Text format     Abstract available


  182. GERNAAT SAM, Ho PJ, Rijnberg N, Emaus MJ, et al
    Risk of death from cardiovascular disease following breast cancer: a systematic review.
    Breast Cancer Res Treat. 2017 May 13. doi: 10.1007/s10549-017-4282.
    PubMed     Text format     Abstract available


  183. JO CHIEN A, Chambers J, Mcauley F, Kaplan T, et al
    Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.
    Breast Cancer Res Treat. 2017 May 13. doi: 10.1007/s10549-017-4288.
    PubMed     Text format     Abstract available


  184. SCANNELL BRYAN M, Argos M, Andrulis IL, Hopper JL, et al
    Limited influence of germline genetic variation on all-cause mortality in women with early onset breast cancer: evidence from gene-based tests, single-marker regression, and whole-genome prediction.
    Breast Cancer Res Treat. 2017 May 13. doi: 10.1007/s10549-017-4287.
    PubMed     Text format     Abstract available


  185. RUMMEL SK, Lovejoy L, Shriver CD, Ellsworth RE, et al
    Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer.
    Breast Cancer Res Treat. 2017 May 13. doi: 10.1007/s10549-017-4291.
    PubMed     Text format     Abstract available


  186. NIEHOFF NM, White AJ, Sandler DP
    Childhood and teenage physical activity and breast cancer risk.
    Breast Cancer Res Treat. 2017 May 12. doi: 10.1007/s10549-017-4276.
    PubMed     Text format     Abstract available


  187. MAXWELL KN, Soucier-Ernst D, Tahirovic E, Troxel AB, et al
    Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.
    Breast Cancer Res Treat. 2017 May 12. doi: 10.1007/s10549-017-4257.
    PubMed     Text format     Abstract available


  188. NERICH V, Saing S, Gamper EM, Holzner B, et al
    Critical appraisal of health-state utility values used in breast cancer-related cost-utility analyses.
    Breast Cancer Res Treat. 2017 May 11. doi: 10.1007/s10549-017-4283.
    PubMed     Text format     Abstract available


  189. LEWIS PHILLIPS GD, Nishimura MC, Lacap JA, Kharbanda S, et al
    Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
    Breast Cancer Res Treat. 2017 May 10. doi: 10.1007/s10549-017-4279.
    PubMed     Text format     Abstract available


  190. RUDDY KJ, Van Houten HK, Sangaralingham LR, Freedman RA, et al
    Impact of treatment regimen on acute care use during and after adjuvant chemotherapy for early-stage breast cancer.
    Breast Cancer Res Treat. 2017 May 10. doi: 10.1007/s10549-017-4280.
    PubMed     Text format     Abstract available


  191. CABARROU B, Mourey L, Dalenc F, Balardy L, et al
    Methodology of phase II clinical trials in metastatic elderly breast cancer: a literature review.
    Breast Cancer Res Treat. 2017 May 9. doi: 10.1007/s10549-017-4278.
    PubMed     Text format     Abstract available


  192. KIM JY, Ok ON, Seo JJ, Lee SH, et al
    A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy.
    Breast Cancer Res Treat. 2017 May 9. doi: 10.1007/s10549-017-4268.
    PubMed     Text format     Abstract available


  193. LU L, Bai Y, Wang Z
    Elevated T cell activation score is associated with improved survival of breast cancer.
    Breast Cancer Res Treat. 2017 May 9. doi: 10.1007/s10549-017-4281.
    PubMed     Text format     Abstract available


  194. HO D, Huang J, Chapman JW, Leitzel K, et al
    Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab).
    Breast Cancer Res Treat. 2017 May 8. doi: 10.1007/s10549-017-4273.
    PubMed     Text format     Abstract available


  195. MUFTAH AA, Aleskandarany MA, Al-Kaabi MM, Sonbul SN, et al
    Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.
    Breast Cancer Res Treat. 2017 May 6. doi: 10.1007/s10549-017-4270.
    PubMed     Text format     Abstract available


  196. JUNG SY, Ho G, Rohan T, Strickler H, et al
    Interaction of insulin-like growth factor-I and insulin resistance-related genetic variants with lifestyle factors on postmenopausal breast cancer risk.
    Breast Cancer Res Treat. 2017 May 6. doi: 10.1007/s10549-017-4272.
    PubMed     Text format     Abstract available


  197. MASALA G, Ambrogetti D, Assedi M, Bendinelli B, et al
    Mammographic breast density and breast cancer risk in a Mediterranean population: a nested case-control study in the EPIC Florence cohort.
    Breast Cancer Res Treat. 2017 May 6. doi: 10.1007/s10549-017-4274.
    PubMed     Text format     Abstract available


  198. YUAN J, Yang Y, Gao Z, Wang Z, et al
    Tyr23 phosphorylation of Anxa2 enhances STAT3 activation and promotes proliferation and invasion of breast cancer cells.
    Breast Cancer Res Treat. 2017 May 3. doi: 10.1007/s10549-017-4271.
    PubMed     Text format     Abstract available


  199. RAPHAEL J, Gandhi S, Li N, Lu FI, et al
    The role of quantitative estrogen receptor status in predicting tumor response at surgery in breast cancer patients treated with neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2017 May 2. doi: 10.1007/s10549-017-4269.
    PubMed     Text format     Abstract available


    April 2017
  200. CHRYSANTHOU E, Gorringe KL, Joseph C, Craze M, et al
    Phenotypic characterisation of breast cancer: the role of CDC42.
    Breast Cancer Res Treat. 2017 Apr 27. doi: 10.1007/s10549-017-4267.
    PubMed     Text format     Abstract available


  201. DELAHAYE LJMJ, Drukker CA, Dreezen C, Witteveen A, et al
    A breast cancer gene signature for indolent disease.
    Breast Cancer Res Treat. 2017 Apr 27. doi: 10.1007/s10549-017-4262.
    PubMed     Text format     Abstract available


  202. SHERI A, Smith IE, Hills M, Jones RL, et al
    Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2017 Apr 26. doi: 10.1007/s10549-017-4266.
    PubMed     Text format     Abstract available


  203. LIU Y, Li ZY, Wang JN, Li X, et al
    Effects of hepatitis C virus infection on the safety of chemotherapy for breast cancer patients.
    Breast Cancer Res Treat. 2017 Apr 26. doi: 10.1007/s10549-017-4259.
    PubMed     Text format     Abstract available


  204. LOHMANN AE, Liebman MF, Brien W, Parulekar WR, et al
    Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32.
    Breast Cancer Res Treat. 2017 Apr 26. doi: 10.1007/s10549-017-4265.
    PubMed     Text format     Abstract available


  205. LOHMANN AE, Ennis M, Taylor SK, Goodwin PJ, et al
    Metabolic factors, anthropometric measures, diet, and physical activity in long-term breast cancer survivors: change from diagnosis and comparison to non-breast cancer controls.
    Breast Cancer Res Treat. 2017 Apr 25. doi: 10.1007/s10549-017-4263.
    PubMed     Text format     Abstract available


  206. CINTOLO-GONZALEZ JA, Braun D, Blackford AL, Mazzola E, et al
    Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications.
    Breast Cancer Res Treat. 2017 Apr 25. doi: 10.1007/s10549-017-4247.
    PubMed     Text format     Abstract available


  207. YOUNG-AFAT DA, van Gils CH, van den Bongard HJGD, Verkooijen HM, et al
    The Utrecht cohort for Multiple BREast cancer intervention studies and Long-term evaLuAtion (UMBRELLA): objectives, design, and baseline results.
    Breast Cancer Res Treat. 2017 Apr 25. doi: 10.1007/s10549-017-4242.
    PubMed     Text format     Abstract available


  208. VON HAGENS C, Walter-Sack I, Goeckenjan M, Osburg J, et al
    Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2).
    Breast Cancer Res Treat. 2017 Apr 24. doi: 10.1007/s10549-017-4261.
    PubMed     Text format     Abstract available


  209. KAIDAR-PERSON O, Zagar TM, Oldan JD, Matney J, et al
    Early cardiac perfusion defects after left-sided radiation therapy for breast cancer: is there a volume response?
    Breast Cancer Res Treat. 2017 Apr 21. doi: 10.1007/s10549-017-4248.
    PubMed     Text format     Abstract available


  210. VAN RAMSHORST MS, Loo CE, Groen EJ, Winter-Warnars GH, et al
    MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2017 Apr 21. doi: 10.1007/s10549-017-4254.
    PubMed     Text format     Abstract available


  211. ALLAIRE BT, Ekwueme DU, Poehler D, Thomas CC, et al
    Breast cancer treatment costs in younger, privately insured women.
    Breast Cancer Res Treat. 2017 Apr 21. doi: 10.1007/s10549-017-4249.
    PubMed     Text format     Abstract available


  212. LIU B, Yi Z, Guan X, Zeng YX, et al
    The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis.
    Breast Cancer Res Treat. 2017 Apr 21. doi: 10.1007/s10549-017-4246.
    PubMed     Text format     Abstract available


  213. DUDENKOV TM, Ingle JN, Buzdar AU, Robson ME, et al
    SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.
    Breast Cancer Res Treat. 2017 Apr 20. doi: 10.1007/s10549-017-4243.
    PubMed     Text format     Abstract available


  214. REYES ME, Fujii T, Branstetter D, Krishnamurthy S, et al
    Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression.
    Breast Cancer Res Treat. 2017 Apr 17. doi: 10.1007/s10549-017-4233.
    PubMed     Text format     Abstract available


  215. SOUCISE A, Vaughn C, Thompson CL, Millen AE, et al
    Sleep quality, duration, and breast cancer aggressiveness.
    Breast Cancer Res Treat. 2017 Apr 17. doi: 10.1007/s10549-017-4245.
    PubMed     Text format     Abstract available


  216. ABDEL-RAHMAN O
    Assessment of the prognostic and discriminating value of the novel bioscore system for breast cancer; a SEER database analysis.
    Breast Cancer Res Treat. 2017 Apr 17. doi: 10.1007/s10549-017-4244.
    PubMed     Text format     Abstract available


  217. HAN J, Choi YL, Kim H, Choi JY, et al
    MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.
    Breast Cancer Res Treat. 2017 Apr 13. doi: 10.1007/s10549-017-4234.
    PubMed     Text format     Abstract available


  218. BALLINGER TJ, Kassem N, Shen F, Jiang G, et al
    Discerning the clinical relevance of biomarkers in early stage breast cancer.
    Breast Cancer Res Treat. 2017 Apr 11. doi: 10.1007/s10549-017-4238.
    PubMed     Text format     Abstract available


  219. KUCHARCZYK MJ, Parpia S, Walker-Dilks C, Banfield L, et al
    Ablative Therapies in Metastatic Breast Cancer: A Systematic Review.
    Breast Cancer Res Treat. 2017 Apr 11. doi: 10.1007/s10549-017-4228.
    PubMed     Text format     Abstract available


  220. GRANT WB
    Racial disparity in vitamin D status may explain racial disparity in survival from estrogen and progesterone receptor-positive breast cancer.
    Breast Cancer Res Treat. 2017 Apr 10. doi: 10.1007/s10549-017-4237.
    PubMed     Text format    


  221. ZHANG X, Brown JC, Paskett ED, Zemel BS, et al
    Changes in arm tissue composition with slowly progressive weight-lifting among women with breast cancer-related lymphedema.
    Breast Cancer Res Treat. 2017 Apr 8. doi: 10.1007/s10549-017-4221.
    PubMed     Text format     Abstract available


  222. MONFORT SM, Pan X, Patrick R, Ramaswamy B, et al
    Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients.
    Breast Cancer Res Treat. 2017 Apr 3. doi: 10.1007/s10549-017-4230.
    PubMed     Text format     Abstract available


  223. DIECI MV, Frassoldati A, Generali D, Bisagni G, et al
    Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
    Breast Cancer Res Treat. 2017 Apr 3. doi: 10.1007/s10549-017-4219.
    PubMed     Text format    


  224. GOMEZ SL, Von Behren J, McKinley M, Clarke CA, et al
    Breast cancer in Asian Americans in California, 1988-2013: increasing incidence trends and recent data on breast cancer subtypes.
    Breast Cancer Res Treat. 2017 Apr 1. doi: 10.1007/s10549-017-4229.
    PubMed     Text format     Abstract available


  225. LEE GE, Mayer EL, Partridge A
    Prognosis of pregnancy-associated breast cancer.
    Breast Cancer Res Treat. 2017 Apr 1. doi: 10.1007/s10549-017-4224.
    PubMed     Text format     Abstract available


  226. ANDREANO A, Rebora P, Valsecchi MG, Russo AG, et al
    Adherence to guidelines and breast cancer patients survival: a population-based cohort study analyzed with a causal inference approach.
    Breast Cancer Res Treat. 2017 Apr 1. doi: 10.1007/s10549-017-4210.
    PubMed     Text format     Abstract available


    March 2017
  227. THOMAS LN, Chedrawe ER, Barnes PJ, Too CK, et al
    Prolactin/androgen-inducible carboxypeptidase-D increases with nitrotyrosine and Ki67 for breast cancer progression in vivo, and upregulates progression markers VEGF-C and Runx2 in vitro.
    Breast Cancer Res Treat. 2017 Mar 31. doi: 10.1007/s10549-017-4223.
    PubMed     Text format     Abstract available


  228. MANDELBLATT JS, Cai L, Luta G, Kimmick G, et al
    Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance).
    Breast Cancer Res Treat. 2017 Mar 31. doi: 10.1007/s10549-017-4222.
    PubMed     Text format     Abstract available


  229. HAMURCU Z, Kahraman N, Ashour A, Ozpolat B, et al
    FOXM1 transcriptionally regulates expression of integrin beta1 in triple-negative breast cancer.
    Breast Cancer Res Treat. 2017 Mar 30. doi: 10.1007/s10549-017-4207.
    PubMed     Text format     Abstract available


  230. MOSHINA N, Sebuodegard S, Hofvind S
    Is breast compression associated with breast cancer detection and other early performance measures in a population-based breast cancer screening program?
    Breast Cancer Res Treat. 2017 Mar 29. doi: 10.1007/s10549-017-4214.
    PubMed     Text format     Abstract available


  231. WOLLSCHLAGER D, Merzenich H, Schwentner L, Janni W, et al
    Self-reported long-term cardiac morbidity in breast cancer patients: a retrospective cohort study in Germany (PASSOS Heart Study).
    Breast Cancer Res Treat. 2017 Mar 28. doi: 10.1007/s10549-017-4215.
    PubMed     Text format     Abstract available


  232. CICCARESE M, Fabi A, Moscetti L, Cazzaniga ME, et al
    Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.
    Breast Cancer Res Treat. 2017 Mar 28. doi: 10.1007/s10549-017-4213.
    PubMed     Text format     Abstract available


  233. LIM Y, Ko ES, Han BK, Ko EY, et al
    Background parenchymal enhancement on breast MRI: association with recurrence-free survival in patients with newly diagnosed invasive breast cancer.
    Breast Cancer Res Treat. 2017 Mar 27. doi: 10.1007/s10549-017-4217.
    PubMed     Text format     Abstract available


  234. HOLCAKOVA J, Nekulova M, Orzol P, Nenutil R, et al
    DeltaNp63 activates EGFR signaling to induce loss of adhesion in triple-negative basal-like breast cancer cells.
    Breast Cancer Res Treat. 2017 Mar 27. doi: 10.1007/s10549-017-4216.
    PubMed     Text format     Abstract available


  235. KRAMMER J, Pinker-Domenig K, Robson ME, Gonen M, et al
    Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2017 Mar 25. doi: 10.1007/s10549-017-4198.
    PubMed     Text format     Abstract available


  236. ASADUZZAMAN M, Constantinou S, Min H, Gallon J, et al
    Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
    Breast Cancer Res Treat. 2017 Mar 24. doi: 10.1007/s10549-017-4202.
    PubMed     Text format     Abstract available


  237. KAWAGUCHI H, Masuda N, Nakayama T, Aogi K, et al
    Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).
    Breast Cancer Res Treat. 2017 Mar 23. doi: 10.1007/s10549-017-4212.
    PubMed     Text format     Abstract available


  238. WU Y, Tran T, Dwabe S, Sarkissyan M, et al
    A83-01 inhibits TGF-beta-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells.
    Breast Cancer Res Treat. 2017 Mar 23. doi: 10.1007/s10549-017-4211.
    PubMed     Text format     Abstract available


  239. STREKALOVA E, Malin D, Rajanala H, Cryns VL, et al
    Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression.
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4201.
    PubMed     Text format     Abstract available


  240. BASELGA J, Morales SM, Awada A, Blum JL, et al
    A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4199.
    PubMed     Text format     Abstract available


  241. KIM GM, Kim S, Park HS, Kim JY, et al
    Chemotherapy-induced irreversible alopecia in early breast cancer patients.
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4204.
    PubMed     Text format     Abstract available


  242. JENDRIAN S, Steffens K, Schmalfeldt B, Laakmann E, et al
    Quality of life in patients with recurrent breast cancer after second breast-conserving therapy in comparison with mastectomy: the German experience.
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4208.
    PubMed     Text format     Abstract available


  243. TRYFONIDIS K, Marreaud S, Khaled H, De Valk B, et al
    Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4203.
    PubMed     Text format     Abstract available


  244. MATTER-WALSTRA K, Schwenkglenks M, Dedes KJ
    Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4209.
    PubMed     Text format    


  245. MUTI P, Secreto G, Krogh V
    Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.
    Breast Cancer Res Treat. 2017 Mar 18. doi: 10.1007/s10549-017-4194.
    PubMed     Text format    


  246. FURLANETTO J, Jackisch C, Untch M, Schneeweiss A, et al
    Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69).
    Breast Cancer Res Treat. 2017 Mar 17. doi: 10.1007/s10549-017-4200.
    PubMed     Text format     Abstract available


  247. BOURKE M, Soden D, Clover AJ
    Effective treatment of intractable cutaneous metastases of breast cancer with electrochemotherapy: a useful contributor to cutaneous disease control.
    Breast Cancer Res Treat. 2017 Mar 17. doi: 10.1007/s10549-017-4187.
    PubMed     Text format    


  248. LIM YJ, Lee SW, Choi N, Kwon J, et al
    Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice.
    Breast Cancer Res Treat. 2017 Mar 17. doi: 10.1007/s10549-017-4206.
    PubMed     Text format     Abstract available


  249. ZHANG S, Gao X, Fu W, Li S, et al
    Immunoglobulin-like domain 4-mediated ligand-independent dimerization triggers VEGFR-2 activation in HUVECs and VEGFR2-positive breast cancer cells.
    Breast Cancer Res Treat. 2017 Mar 16. doi: 10.1007/s10549-017-4189.
    PubMed     Text format     Abstract available


  250. TSENG LM, Chiu JH, Liu CY, Tsai YF, et al
    A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women.
    Breast Cancer Res Treat. 2017 Mar 15. doi: 10.1007/s10549-017-4195.
    PubMed     Text format     Abstract available


  251. GERSHUNI V, Li YR, Williams AD, So A, et al
    Breast cancer subtype distribution is different in normal weight, overweight, and obese women.
    Breast Cancer Res Treat. 2017 Mar 14. doi: 10.1007/s10549-017-4192.
    PubMed     Text format     Abstract available


  252. DIECI MV, Frassoldati A, Generali D, Bisagni G, et al
    Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
    Breast Cancer Res Treat. 2017 Mar 13. doi: 10.1007/s10549-017-4191.
    PubMed     Text format     Abstract available


  253. KIMMICK GG, Major B, Clapp J, Sloan J, et al
    Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503).
    Breast Cancer Res Treat. 2017 Mar 10. doi: 10.1007/s10549-017-4188.
    PubMed     Text format     Abstract available


  254. YANAGAWA T, Kagara N, Miyake T, Tanei T, et al
    Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing.
    Breast Cancer Res Treat. 2017 Mar 10. doi: 10.1007/s10549-017-4190.
    PubMed     Text format     Abstract available


  255. KJARTANSDOTTIR OJ, Sigurdardottir LG, Olafsdottir EJ, Jonasson JG, et al
    Estrogen-progestin use and breast cancer characteristics in lean and overweight postmenopausal women.
    Breast Cancer Res Treat. 2017 Mar 9. doi: 10.1007/s10549-017-4171.
    PubMed     Text format     Abstract available


  256. RUGO HS, Melin SA, Voigt J
    Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis.
    Breast Cancer Res Treat. 2017 Mar 8. doi: 10.1007/s10549-017-4185.
    PubMed     Text format     Abstract available


  257. CAMPANA LG, Galuppo S, Valpione S
    Treatment of cutaneous metastases of breast cancer with electrochemotherapy: what is the magnitude of clinical benefit?
    Breast Cancer Res Treat. 2017 Mar 8. doi: 10.1007/s10549-017-4186.
    PubMed     Text format    


  258. CONWAY K, Edmiston SN, Parrish E, Bryant C, et al
    Breast tumor DNA methylation patterns associated with smoking in the Carolina Breast Cancer Study.
    Breast Cancer Res Treat. 2017 Mar 8. doi: 10.1007/s10549-017-4178.
    PubMed     Text format     Abstract available


  259. BINGHAM C, Fernandez SV, Fittipaldi P, Dempsey PW, et al
    Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients.
    Breast Cancer Res Treat. 2017 Mar 7. doi: 10.1007/s10549-017-4176.
    PubMed     Text format     Abstract available


  260. CORNELISSEN AJ, Kool M, Lopez Penha TR, Keuter XH, et al
    Lymphatico-venous anastomosis as treatment for breast cancer-related lymphedema: a prospective study on quality of life.
    Breast Cancer Res Treat. 2017 Mar 7. doi: 10.1007/s10549-017-4180.
    PubMed     Text format     Abstract available


  261. LEOPOLD RB, Thomas AW, Concannon KF, Correll AD, et al
    Breast cancer screening in patients with cancers other than breast.
    Breast Cancer Res Treat. 2017 Mar 6. doi: 10.1007/s10549-017-4179.
    PubMed     Text format     Abstract available


  262. ENGSTROM MJ, Valla M, Bofin AM
    Basal markers and prognosis in luminal breast cancer.
    Breast Cancer Res Treat. 2017 Mar 3. doi: 10.1007/s10549-017-4182.
    PubMed     Text format     Abstract available


  263. VADAPARAMPIL ST, Christie J, Donovan KA, Kim J, et al
    Health-related quality of life in Black breast cancer survivors with and without triple-negative breast cancer (TNBC).
    Breast Cancer Res Treat. 2017 Mar 3. doi: 10.1007/s10549-017-4173.
    PubMed     Text format     Abstract available


  264. RAUSCHER GH, Silva A, Pauls H, Frasor J, et al
    Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities.
    Breast Cancer Res Treat. 2017 Mar 1. doi: 10.1007/s10549-017-4166.
    PubMed     Text format     Abstract available


  265. SALGADO TM, Davis EJ, Farris KB, Fawaz S, et al
    Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer.
    Breast Cancer Res Treat. 2017 Mar 1. doi: 10.1007/s10549-017-4177.
    PubMed     Text format     Abstract available


    February 2017
  266. RAPHAEL J, Paramsothy T, Li N, Lee J, et al
    A single-institution experience of salvage therapy for patients with early and locally advanced breast cancer who progress during neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2017 Feb 27. doi: 10.1007/s10549-017-4167.
    PubMed     Text format     Abstract available


  267. MATSUDA N, Lim B, Wang Y, Krishnamurthy S, et al
    Identification of frequent somatic mutations in inflammatory breast cancer.
    Breast Cancer Res Treat. 2017 Feb 27. doi: 10.1007/s10549-017-4165.
    PubMed     Text format     Abstract available


  268. ORUCEVIC A, Bell JL, McNabb AP, Heidel RE, et al
    Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
    Breast Cancer Res Treat. 2017 Feb 27. doi: 10.1007/s10549-017-4170.
    PubMed     Text format     Abstract available


  269. ROBERTS MC, Miller DP, Shak S, Petkov VI, et al
    Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
    Breast Cancer Res Treat. 2017 Feb 27. doi: 10.1007/s10549-017-4162.
    PubMed     Text format     Abstract available


  270. PARK HS, Sohn J, Kim SI, Park S, et al
    Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Feb 27. doi: 10.1007/s10549-017-4175.
    PubMed     Text format     Abstract available


  271. CHAKRABORTY A, Hatzis C, DiGiovanna MP
    Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease.
    Breast Cancer Res Treat. 2017 Feb 24. doi: 10.1007/s10549-017-4169.
    PubMed     Text format     Abstract available


  272. YEONG J, Thike AA, Lim JC, Lee B, et al
    Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer.
    Breast Cancer Res Treat. 2017 Feb 23. doi: 10.1007/s10549-017-4161.
    PubMed     Text format     Abstract available


  273. IGNATOV T, Eggemann H, Burger E, Costa SD, et al
    Management of small T1a/b breast cancer by tumor subtype.
    Breast Cancer Res Treat. 2017 Feb 23. doi: 10.1007/s10549-017-4168.
    PubMed     Text format     Abstract available


  274. ZETTERLUND LH, Frisell J, Zouzos A, Axelsson R, et al
    Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer.
    Breast Cancer Res Treat. 2017 Feb 21. doi: 10.1007/s10549-017-4164.
    PubMed     Text format     Abstract available


  275. LIEU TA, Ray GT, Prausnitz SR, Habel LA, et al
    Oncologist and organizational factors associated with variation in breast cancer multigene testing.
    Breast Cancer Res Treat. 2017 Feb 21. doi: 10.1007/s10549-017-4158.
    PubMed     Text format     Abstract available


  276. GASTELUM GM, Iqbal C, Hilsenbeck SG, Rimawi MF, et al
    Retrospective review of genomic testing in breast cancer: Does it improve outcome?
    Breast Cancer Res Treat. 2017 Feb 21. doi: 10.1007/s10549-017-4154.
    PubMed     Text format     Abstract available


  277. VAN NIJNATTEN TJ, Simons JM, Moossdorff M, de Munck L, et al
    Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases.
    Breast Cancer Res Treat. 2017 Feb 17. doi: 10.1007/s10549-017-4157.
    PubMed     Text format     Abstract available


  278. ZETTERLUND L, Celebioglu F, Axelsson R, de Boniface J, et al
    Swedish prospective multicenter trial on the accuracy and clinical relevance of sentinel lymph node biopsy before neoadjuvant systemic therapy in breast cancer.
    Breast Cancer Res Treat. 2017 Feb 17. doi: 10.1007/s10549-017-4163.
    PubMed     Text format     Abstract available


  279. PARISE CA, Caggiano V
    Risk factors associated with the triple-negative breast cancer subtype within four race/ethnicities.
    Breast Cancer Res Treat. 2017 Feb 17. doi: 10.1007/s10549-017-4159.
    PubMed     Text format     Abstract available


  280. PARK B, Sohn JY, Yoon KA, Lee KS, et al
    Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients.
    Breast Cancer Res Treat. 2017 Feb 15. doi: 10.1007/s10549-017-4142.
    PubMed     Text format     Abstract available


  281. GOORTS B, van Nijnatten TJ, de Munck L, Moossdorff M, et al
    Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients.
    Breast Cancer Res Treat. 2017 Feb 15. doi: 10.1007/s10549-017-4155.
    PubMed     Text format     Abstract available


  282. HSIEH YC, Tu SH, Su CT, Cho EC, et al
    A polygenic risk score for breast cancer risk in a Taiwanese population.
    Breast Cancer Res Treat. 2017 Feb 15. doi: 10.1007/s10549-017-4144.
    PubMed     Text format     Abstract available


  283. INWALD EC, Ortmann O, Koller M, Zeman F, et al
    Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology.
    Breast Cancer Res Treat. 2017 Feb 15. doi: 10.1007/s10549-017-4151.
    PubMed     Text format     Abstract available


  284. LERNER-ELLIS J, Donenberg T, Ahmed H, George S, et al
    A high frequency of PALB2 mutations in Jamaican patients with breast cancer.
    Breast Cancer Res Treat. 2017 Feb 13. doi: 10.1007/s10549-017-4148.
    PubMed     Text format     Abstract available


  285. HWANG KT, Kim YA, Kim J, Chu AJ, et al
    The influences of peritumoral lymphatic invasion and vascular invasion on the survival and recurrence according to the molecular subtypes of breast cancer.
    Breast Cancer Res Treat. 2017 Feb 13. doi: 10.1007/s10549-017-4153.
    PubMed     Text format     Abstract available


  286. THOMAS JS, Hanby AM, Russell N, van Tienhoven G, et al
    The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer.
    Breast Cancer Res Treat. 2017 Feb 11. doi: 10.1007/s10549-017-4145.
    PubMed     Text format     Abstract available


  287. MARINAC CR, Nelson SH, Flatt SW, Natarajan L, et al
    Sleep duration and breast cancer prognosis: perspectives from the Women's Healthy Eating and Living Study.
    Breast Cancer Res Treat. 2017 Feb 11. doi: 10.1007/s10549-017-4140.
    PubMed     Text format     Abstract available


  288. LIM EA, Gunther JE, Kim HK, Flexman M, et al
    Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients.
    Breast Cancer Res Treat. 2017 Feb 11. doi: 10.1007/s10549-017-4150.
    PubMed     Text format     Abstract available


  289. YEO SK, French R, Spada F, Clarkson R, et al
    Opposing roles of Nfkb2 gene products p100 and p52 in the regulation of breast cancer stem cells.
    Breast Cancer Res Treat. 2017 Feb 11. doi: 10.1007/s10549-017-4149.
    PubMed     Text format     Abstract available


  290. SONG SE, Shin SU, Moon HG, Ryu HS, et al
    MR imaging features associated with distant metastasis-free survival of patients with invasive breast cancer: a case-control study.
    Breast Cancer Res Treat. 2017 Feb 9. doi: 10.1007/s10549-017-4143.
    PubMed     Text format     Abstract available


  291. SHAITELMAN SF, Chiang YJ, Griffin KD, De Snyder SM, et al
    Erratum to: Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis.
    Breast Cancer Res Treat. 2017 Feb 9. doi: 10.1007/s10549-017-4116.
    PubMed     Text format    


  292. PARIKH RP, Odom EB, Yu L, Colditz GA, et al
    Complications and thromboembolic events associated with tamoxifen therapy in patients with breast cancer undergoing microvascular breast reconstruction: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2017 Feb 9. doi: 10.1007/s10549-017-4146.
    PubMed     Text format     Abstract available


  293. TAMAKI K, Fukuyama AK, Terukina S, Kamada Y, et al
    Randomized trial of aromatherapy versus conventional care for breast cancer patients during perioperative periods.
    Breast Cancer Res Treat. 2017 Feb 8. doi: 10.1007/s10549-017-4134.
    PubMed     Text format     Abstract available


  294. RAYCHAUDHURI M, Bronger H, Buchner T, Kiechle M, et al
    MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
    Breast Cancer Res Treat. 2017 Feb 8. doi: 10.1007/s10549-017-4132.
    PubMed     Text format     Abstract available


  295. IWATA H, Masuda N, Yamamoto D, Sagara Y, et al
    Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Feb 8. doi: 10.1007/s10549-017-4138.
    PubMed     Text format     Abstract available


  296. STEINDORF K, Wiskemann J, Ulrich CM, Schmidt ME, et al
    Effects of exercise on sleep problems in breast cancer patients receiving radiotherapy: a randomized clinical trial.
    Breast Cancer Res Treat. 2017 Feb 8. doi: 10.1007/s10549-017-4141.
    PubMed     Text format     Abstract available


  297. MEHTA GA, Parker JS, Silva GO, Hoadley KA, et al
    Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer.
    Breast Cancer Res Treat. 2017 Feb 7. doi: 10.1007/s10549-017-4139.
    PubMed     Text format     Abstract available


  298. HIGGINS M, Curigliano G, Dieras V, Kuemmel S, et al
    Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study.
    Breast Cancer Res Treat. 2017 Feb 7. doi: 10.1007/s10549-017-4130.
    PubMed     Text format     Abstract available


  299. CESPEDES FELICIANO EM, Kwan ML, Kushi LH, Weltzien EK, et al
    Adiposity, post-diagnosis weight change, and risk of cardiovascular events among early-stage breast cancer survivors.
    Breast Cancer Res Treat. 2017 Feb 7. doi: 10.1007/s10549-017-4133.
    PubMed     Text format     Abstract available


  300. WITZEL I, Marx AK, Muller V, Wikman H, et al
    Role of HYAL1 expression in primary breast cancer in the formation of brain metastases.
    Breast Cancer Res Treat. 2017 Feb 6. doi: 10.1007/s10549-017-4135.
    PubMed     Text format     Abstract available


  301. VALLE LF, Agarwal S, Bickel KE, Herchek HA, et al
    Hypofractionated whole breast radiotherapy in breast conservation for early-stage breast cancer: a systematic review and meta-analysis of randomized trials.
    Breast Cancer Res Treat. 2017 Feb 3. doi: 10.1007/s10549-017-4118.
    PubMed     Text format     Abstract available


  302. NYROP KA, Deal AM, Lee JT, Muss HB, et al
    Weight changes in postmenopausal breast cancer survivors over 2 years of endocrine therapy: a retrospective chart review.
    Breast Cancer Res Treat. 2017 Feb 2. doi: 10.1007/s10549-017-4106.
    PubMed     Text format     Abstract available


  303. HAMILTON JG, Genoff MC, Salerno M, Amoroso K, et al
    Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer.
    Breast Cancer Res Treat. 2017 Feb 1. doi: 10.1007/s10549-017-4123.
    PubMed     Text format     Abstract available


  304. LEE JA, Yoo JE, Park HS
    Metabolic syndrome and incidence of breast cancer in middle-aged Korean women: a nationwide cohort study.
    Breast Cancer Res Treat. 2017 Feb 1. doi: 10.1007/s10549-017-4131.
    PubMed     Text format     Abstract available


    January 2017
  305. DETHLEFSEN C, Pedersen KS, Hojman P
    Every exercise bout matters: linking systemic exercise responses to breast cancer control.
    Breast Cancer Res Treat. 2017 Jan 30. doi: 10.1007/s10549-017-4129.
    PubMed     Text format     Abstract available


  306. CARMICHAEL H, Matsen C, Freer P, Kohlmann W, et al
    Breast cancer screening of pregnant and breastfeeding women with BRCA mutations.
    Breast Cancer Res Treat. 2017 Jan 30. doi: 10.1007/s10549-017-4122.
    PubMed     Text format     Abstract available


  307. VAN UDEN DJ, Bretveld R, Siesling S, de Wilt JH, et al
    Inflammatory breast cancer in the Netherlands; improved survival over the last decades.
    Breast Cancer Res Treat. 2017 Jan 30. doi: 10.1007/s10549-017-4119.
    PubMed     Text format     Abstract available


  308. PEREZ M, Schootman M, Hall LE, Jeffe DB, et al
    Accelerated partial breast irradiation compared with whole breast radiation therapy: a breast cancer cohort study measuring change in radiation side-effects severity and quality of life.
    Breast Cancer Res Treat. 2017 Jan 28. doi: 10.1007/s10549-017-4121.
    PubMed     Text format     Abstract available


  309. VALLA M, Engstrom MJ, Ytterhus B, Hansen AK, et al
    FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis.
    Breast Cancer Res Treat. 2017 Jan 25. doi: 10.1007/s10549-017-4125.
    PubMed     Text format     Abstract available


  310. DEN BROK WD, Speers CH, Gondara L, Baxter E, et al
    Response to "Do metastasis-free interval less or more than 24 months for recurrent metastatic breast cancer and primary surgery for de novo metastatic breast cancer matter for survival?"
    Breast Cancer Res Treat. 2017 Jan 21. doi: 10.1007/s10549-017-4114.
    PubMed     Text format    


  311. MA D, Jiang YZ, Liu XY, Liu YR, et al
    Clinical and molecular relevance of mutant-allele tumor heterogeneity in breast cancer.
    Breast Cancer Res Treat. 2017 Jan 16. doi: 10.1007/s10549-017-4113.
    PubMed     Text format     Abstract available


  312. ALTUNDAG K
    Do metastasis-free interval less or more than 24 months for recurrent metastatic breast cancer and primary surgery for de novo metastatic breast cancer matter for survival?
    Breast Cancer Res Treat. 2017 Jan 16. doi: 10.1007/s10549-017-4109.
    PubMed     Text format    


  313. RIZZOLO P, Silvestri V, Ottini L
    Retesting BRCA1/BRCA2 mutation negative male breast cancer patients using next generation sequencing technologies.
    Breast Cancer Res Treat. 2017 Jan 16. doi: 10.1007/s10549-017-4108.
    PubMed     Text format    


  314. MATSUO S, Watanabe J, Mitsuya K, Hayashi N, et al
    Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up.
    Breast Cancer Res Treat. 2017 Jan 13. doi: 10.1007/s10549-017-4107.
    PubMed     Text format     Abstract available


  315. GULDBERG TL, Christensen S, Zachariae R, Jensen AB, et al
    Prognostic factors in early breast cancer associated with body mass index, physical functioning, physical activity, and comorbidity: data from a nationwide Danish cohort.
    Breast Cancer Res Treat. 2017 Jan 11. doi: 10.1007/s10549-016-4099.
    PubMed     Text format     Abstract available


  316. LEONE BA, Leone J, Leone JP
    Breast cancer is a systemic disease rather than an anatomical process.
    Breast Cancer Res Treat. 2017 Jan 9. doi: 10.1007/s10549-017-4104.
    PubMed     Text format    


  317. HEO J, Chun M, Oh YT, Noh OK, et al
    Psychiatric comorbidities among breast cancer survivors in South Korea: a nationwide population-based study.
    Breast Cancer Res Treat. 2017 Jan 7. doi: 10.1007/s10549-016-4097.
    PubMed     Text format     Abstract available


  318. RADMANESH H, Spethmann T, Enssen J, Schurmann P, et al
    Assessment of an APOBEC3B truncating mutation, c.783delG, in patients with breast cancer.
    Breast Cancer Res Treat. 2017 Jan 6. doi: 10.1007/s10549-016-4100.
    PubMed     Text format     Abstract available


  319. ALTUNDAG K
    The effects of laterality in stage IV breast cancer patients at initial diagnosis; much work is needed!
    Breast Cancer Res Treat. 2017 Jan 6. doi: 10.1007/s10549-017-4103.
    PubMed     Text format    


  320. RAMANATHAN R, Olex AL, Dozmorov M, Bear HD, et al
    Angiopoietin pathway gene expression associated with poor breast cancer survival.
    Breast Cancer Res Treat. 2017 Jan 6. doi: 10.1007/s10549-017-4102.
    PubMed     Text format     Abstract available


  321. EGELAND EV, Boye K, Park D, Synnestvedt M, et al
    Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer.
    Breast Cancer Res Treat. 2017 Jan 5. doi: 10.1007/s10549-016-4096.
    PubMed     Text format     Abstract available


  322. TSANG JY, Au WL, Lo KY, Ni YB, et al
    PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Breast Cancer Res Treat. 2017 Jan 5. doi: 10.1007/s10549-016-4095.
    PubMed     Text format     Abstract available


  323. KAKUGAWA Y, Tada H, Kawai M, Suzuki T, et al
    Associations of obesity and physical activity with serum and intratumoral sex steroid hormone levels among postmenopausal women with breast cancer: analysis of paired serum and tumor tissue samples.
    Breast Cancer Res Treat. 2017 Jan 2. doi: 10.1007/s10549-016-4094.
    PubMed     Text format     Abstract available


    December 2016
  324. ECHAVARRIA I, Granja M, Bueno C, Lopez-Tarruella S, et al
    Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer.
    Breast Cancer Res Treat. 2016 Dec 31. doi: 10.1007/s10549-016-4098.
    PubMed     Text format     Abstract available


  325. OTSUJI K, Sasaki T, Tanaka A, Kunita A, et al
    Use of droplet digital PCR for quantitative and automatic analysis of the HER2 status in breast cancer patients.
    Breast Cancer Res Treat. 2016 Dec 30. doi: 10.1007/s10549-016-4092.
    PubMed     Text format     Abstract available


  326. SHAITELMAN SF
    Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis.
    Breast Cancer Res Treat. 2016 Dec 23. doi: 10.1007/s10549-016-4089.
    PubMed     Text format     Abstract available


  327. LI Y, Kurian AW, Bondarenko I, Taylor JM, et al
    The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients.
    Breast Cancer Res Treat. 2016 Dec 23. doi: 10.1007/s10549-016-4086.
    PubMed     Text format     Abstract available


  328. PRITZLAFF M, Summerour P, McFarland R, Li S, et al
    Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
    Breast Cancer Res Treat. 2016 Dec 22. doi: 10.1007/s10549-016-4085.
    PubMed     Text format     Abstract available


  329. YAMAMOTO D, Sato N, Rai Y, Yamamoto Y, et al
    Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial.
    Breast Cancer Res Treat. 2016 Dec 22. doi: 10.1007/s10549-016-4075.
    PubMed     Text format     Abstract available


  330. DE VRIES SCHULTINK AH, Alexi X, van Werkhoven E, Madlensky L, et al
    An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.
    Breast Cancer Res Treat. 2016 Dec 22. doi: 10.1007/s10549-016-4083.
    PubMed     Text format     Abstract available


  331. SHIAO J, Thomas KM, Rahimi AS, Rao R, et al
    Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients.
    Breast Cancer Res Treat. 2016 Dec 22. doi: 10.1007/s10549-016-4081.
    PubMed     Text format     Abstract available


  332. HAWLEY ST, Janz NK, Griffith KA, Jagsi R, et al
    Recurrence risk perception and quality of life following treatment of breast cancer.
    Breast Cancer Res Treat. 2016 Dec 21. doi: 10.1007/s10549-016-4082.
    PubMed     Text format     Abstract available


  333. BERTOLI G, Cava C, Diceglie C, Martelli C, et al
    MicroRNA-567 dysregulation contributes to carcinogenesis of breast cancer, targeting tumor cell proliferation, and migration.
    Breast Cancer Res Treat. 2016 Dec 20. doi: 10.1007/s10549-016-4079.
    PubMed     Text format     Abstract available


  334. DEN BROK WD, Speers CH, Gondara L, Baxter E, et al
    Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
    Breast Cancer Res Treat. 2016 Dec 20. doi: 10.1007/s10549-016-4080.
    PubMed     Text format     Abstract available


  335. LEONE BA, Vallejo CT, Romero AO, Machiavelli MR, et al
    Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  336. LI S, Liu J, Virnig BA, Collins AJ, et al
    Association between adjuvant chemotherapy and risk of acute kidney injury in elderly women diagnosed with early-stage breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  337. UHM KE, Yoo JS, Chung SH, Lee JD, et al
    Effects of exercise intervention in breast cancer patients: is mobile health (mHealth) with pedometer more effective than conventional program using brochure?
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  338. VAN GELDER M, Vanclee A, van Elssen CH, Hupperets P, et al
    Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  339. YAO S, Zhang Y, Tang L, Roh JM, et al
    Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  340. ADEMUYIWA FO, Tao Y, Luo J, Weilbaecher K, et al
    Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  341. HABRAKEN V, van Nijnatten TJ, de Munck L, Moossdorff M, et al
    Does the TNM classification of solitary internal mammary lymph node metastases in breast cancer still apply?
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  342. ZICK SM, Colacino J, Cornellier M, Khabir T, et al
    Fatigue reduction diet in breast cancer survivors: a pilot randomized clinical trial.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  343. TAVERA-TAPIA A, Perez-Cabornero L, Macias JA, Ceballos MI, et al
    Almost 2% of Spanish breast cancer families are associated to germline pathogenic mutations in the ATM gene.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  344. CHUNG YR, Kim HJ, Jang MH, Park SY, et al
    Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


    November 2016
  345. SAITO R, Miki Y, Hata S, Ishida T, et al
    Aryl hydrocarbon receptor induced intratumoral aromatase in breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  346. LI X, Yang J, Peng L, Sahin AA, et al
    Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  347. SAGARA A, Igarashi K, Otsuka M, Kodama A, et al
    Endocan as a prognostic biomarker of triple-negative breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  348. WANG RX, Chen S, Jin X, Chen CM, et al
    Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  349. ELSHOF LE, Schaapveld M, Schmidt MK, Rutgers EJ, et al
    Erratum to: Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  350. BOURKE MG, Salwa SP, Sadadcharam M, Whelan MC, et al
    Effective treatment of intractable cutaneous metastases of breast cancer with electrochemotherapy: Ten-year audit of single centre experience.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  351. FREEDMAN RA, Seisler DK, Foster JC, Sloan JA, et al
    Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  352. ALTUNDAG K
    First-line all-oral NORCAP (vinorelbine/capecitabine) might be alternative to taxane-based chemotherapy for HER2-negative metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  353. HUANG J, Woods P, Normolle D, Goff JP, et al
    Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  354. SHI M, O'Brien KM, Sandler DP, Taylor JA, et al
    Previous GWAS hits in relation to young-onset breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  355. MCNAMARA KM, Oguro S, Omata F, Kikuchi K, et al
    The presence and impact of estrogen metabolism on the biology of triple-negative breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  356. CONNOR AE, Visvanathan K, Baumgartner KB, Baumgartner RN, et al
    Pre-diagnostic breastfeeding, adiposity, and mortality among parous Hispanic and non-Hispanic white women with invasive breast cancer: the Breast Cancer Health Disparities Study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  357. MASALA G, Bendinelli B, Assedi M, Occhini D, et al
    Up to one-third of breast cancer cases in post-menopausal Mediterranean women might be avoided by modifying lifestyle habits: the EPIC Italy study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  358. CALIP GS, Elmore JG, Boudreau DM
    Characteristics associated with nonadherence to medications for hypertension, diabetes, and dyslipidemia among breast cancer survivors.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  359. AMARA D, Wolf DM, van 't Veer L, Esserman L, et al
    Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  360. CHOWDHURY M, Euhus D, Onega T, Biswas S, et al
    A model for individualized risk prediction of contralateral breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  361. BRAUNSTEIN LZ, Taghian AG, Niemierko A, Salama L, et al
    Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  362. JANKOWSKI C, Guiu S, Cortet M, Charon-Barra C, et al
    Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  363. MERZENICH H, Bartkowiak D, Schmidberger H, Schmidt M, et al
    3D conformal radiotherapy is not associated with the long-term cardiac mortality in breast cancer patients: a retrospective cohort study in Germany (PASSOS-Heart Study).
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


    October 2016
  364. HARBECK N, Saupe S, Jager E, Schmidt M, et al
    A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  365. MORAN O, Nikitina D, Royer R, Poll A, et al
    Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  366. HAMDI Y, Soucy P, Kuchenbaeker KB, Pastinen T, et al
    Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  367. IQBAL J, Ginsburg O, Giannakeas V, Rochon PA, et al
    The impact of nodal micrometastasis on mortality among women with early-stage breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  368. JANSSEN N, Fortis SP, Speigl L, Haritos C, et al
    Peripheral T cell responses to tumour antigens are associated with molecular, immunogenetic and cellular features of breast cancer patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  369. GAUTAM J, Bae YK, Kim JA
    Up-regulation of cathepsin S expression by HSP90 and 5-HT7 receptor-dependent serotonin signaling correlates with triple negativity of human breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  370. CHLEBOWSKI RT, Pan K, Col NF
    Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  371. FERNANDES R, Mazzarello S, Stober C, Vandermeer L, et al
    Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  372. KIM H, Cho DY, Choi DH, Oh M, et al
    Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  373. KOTSOPOULOS J, Singer C, Narod SA
    Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  374. DUGUE PA, Milne RL, Southey MC
    A prospective study of peripheral blood DNA methylation at RPTOR, MGRN1 and RAPSN and risk of breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  375. WANG C, Mu Z, Chervoneva I, Austin L, et al
    Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  376. CHENG F, Zhao J, Hanker AB, Brewer MR, et al
    Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  377. NEUHOUSER ML, Smith AW, George SM, Gibson JT, et al
    Use of complementary and alternative medicine and breast cancer survival in the Health, Eating, Activity, and Lifestyle Study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  378. SCHONBERG MA, Li VW, Eliassen AH, Davis RB, et al
    Accounting for individualized competing mortality risks in estimating postmenopausal breast cancer risk.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  379. PETRELLI F, Barni S, Bregni G, de Braud F, et al
    Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  380. CHURILLA TM, Egleston BL, Murphy CT, Sigurdson ER, et al
    Erratum to: Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  381. LEE JS, Magbanua MJ, Park JW
    Circulating tumor cells in breast cancer: applications in personalized medicine.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  382. BRZEZINSKA M, Williams LJ, Thomas J, Michael Dixon J, et al
    Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  383. DICKENS C, Pfeiffer RM, Anderson WF, Duarte R, et al
    Investigation of breast cancer sub-populations in black and white women in South Africa.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  384. CHEON H, Kim HJ, Lee SW, Kim DH, et al
    Internal mammary node adenopathy on breast MRI and PET/CT for initial staging in patients with operable breast cancer: prevalence and associated factors.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  385. CAZZANIGA ME, Cortesi L, Ferzi A, Scaltriti L, et al
    Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  386. HENNIGS A, Riedel F, Marme F, Sinn P, et al
    Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  387. LANCZKY A, Nagy A, Bottai G, Munkacsy G, et al
    miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  388. VAN MAAREN MC, de Munck L, Jobsen JJ, Poortmans P, et al
    Breast-conserving therapy versus mastectomy in T1-2N2 stage breast cancer: a population-based study on 10-year overall, relative, and distant metastasis-free survival in 3071 patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  389. LI Z, Heng J, Yan J, Guo X, et al
    Integrated analysis of gene expression and methylation profiles of 48 candidate genes in breast cancer patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  390. NORDENSKJOLD A, Fohlin H, Fornander T, Lofdahl B, et al
    Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  391. REIX N, Malina C, Chenard MP, Bellocq JP, et al
    A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  392. HERVIK JB, Stub T
    Adverse effects of non-hormonal pharmacological interventions in breast cancer survivors, suffering from hot flashes: A systematic review and meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  393. GOLSHAN M, Cirrincione CT, Sikov WM, Carey LA, et al
    Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  394. POLLOCK YG, Blackford AL, Jeter SC, Wright J, et al
    Adjuvant radiation use in older women with early-stage breast cancer at Johns Hopkins.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  395. ELSHOF LE, Schaapveld M, Schmidt MK, Rutgers EJ, et al
    Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.
    Breast Cancer Res Treat. 2016;159:553-63.
    PubMed     Text format     Abstract available


  396. DEUTSCH TM, Riethdorf S, Nees J, Hartkopf AD, et al
    Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  397. ALIMUJIANG A, Mo M, Liu Y, Huang NS, et al
    The association between China's Great famine and risk of breast cancer according to hormone receptor status: a hospital-based study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


    September 2016
  398. LEOPOLD C, Wagner AK, Zhang F, Lu CY, et al
    Erratum to: Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  399. ARISTEI C, Kaidar-Person O, Arenas M, Coles C, et al
    The 2016 Assisi Think Tank Meeting on breast cancer: white paper.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  400. HARTMAN EK, Eslick GD
    The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  401. TIAINEN S, Oikari S, Tammi M, Rilla K, et al
    High extent of O-GlcNAcylation in breast cancer cells correlates with the levels of HAS enzymes, accumulation of hyaluronan, and poor outcome.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  402. VAN DER POL CC, Lacle MM, Witkamp AJ, Kornegoor R, et al
    Prognostic models in male breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  403. BEABER EF, Tosteson AN, Haas JS, Onega T, et al
    Breast cancer screening initiation after turning 40 years of age within the PROSPR consortium.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  404. YANG EJ, Ahn S, Kim EK, Kang E, et al
    Use of a prospective surveillance model to prevent breast cancer treatment-related lymphedema: a single-center experience.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  405. KONO M, Fujii T, Lyons GR, Huo L, et al
    Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  406. ZHENG Q, Xia W, Lu Q, Hong R, et al
    Prognostic value of endocrine treatment-related symptoms in patients with breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  407. JOHNSTON S, Basik M, Hegg R, Lausoontornsiri W, et al
    Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naive advanced breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  408. DIABY V, Adunlin G, Ali AA, Zeichner SB, et al
    Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  409. CEJALVO JM, Perez-Fidalgo JA, Ribas G, Burgues O, et al
    Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  410. ENG LG, Dawood S, Sopik V, Haaland B, et al
    Ten-year survival in women with primary stage IV breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  411. FREDHOLM H, Magnusson K, Lindstrom LS, Garmo H, et al
    Long-term outcome in young women with breast cancer: a population-based study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  412. CATUCCI I, Casadei S, Ding YC, Volorio S, et al
    Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  413. TSUYUKI S, Senda N, Kanng Y, Yamaguchi A, et al
    Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  414. SISCO M, Kyrillos AM, Lapin BR, Wang CE, et al
    Trends and variation in the use of nipple-sparing mastectomy for breast cancer in the United States.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  415. O'SULLIVAN CC, Lindenberg M, Bryla C, Patronas N, et al
    ANG1005 for breast cancer brain metastases: correlation between 18F-FLT-PET after first cycle and MRI in response assessment.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  416. O'NEAL J, Clem A, Reynolds L, Dougherty S, et al
    Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  417. HAINSWORTH JD, Murphy PB, Alemar JR, Daniel BR, et al
    Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  418. RAPHAEL MJ, Biagi JJ, Kong W, Mates M, et al
    The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  419. WONG EM, Joo JE, McLean CA, Baglietto L, et al
    Analysis of the breast cancer methylome using formalin-fixed paraffin-embedded tumour.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  420. DETHLEFSEN C, Lillelund C, Midtgaard J, Andersen C, et al
    Exercise regulates breast cancer cell viability: systemic training adaptations versus acute exercise responses.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  421. SAMUEL CA, Pinheiro LC, Reeder-Hayes KE, Walker JS, et al
    To be young, Black, and living with breast cancer: a systematic review of health-related quality of life in young Black breast cancer survivors.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  422. HAMY AS, Bieche I, Lehmann-Che J, Scott V, et al
    BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  423. RYU JM, Lee HJ, Yoon TI, Lee ES, et al
    Breast cancer-specific mortality in small-sized tumor with node-positive breast cancer: a nation-wide study in Korean breast cancer society.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  424. PINHEIRO LC, Samuel CA, Reeder-Hayes KE, Wheeler SB, et al
    Understanding racial differences in health-related quality of life in a population-based cohort of breast cancer survivors.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


    August 2016
  425. COHN BA, Terry MB, Plumb M, Cirillo PM, et al
    Erratum to: Exposure to polychlorinated biphenyl (PCB) congeners measured shortly after giving birth and subsequent risk of maternal breast cancer before age 50.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  426. YOUNIS T, Rayson D, Jovanovic S, Skedgel C, et al
    Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  427. NERICH V, Saing S, Gamper EM, Kemmler G, et al
    Cost-utility analyses of drug therapies in breast cancer: a systematic review.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  428. FENG J, Xu G, Liu J, Zhang N, et al
    Phosphorylation of LSD1 at Ser112 is crucial for its function in induction of EMT and metastasis in breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  429. LE QA, Bae YH, Kang JH
    Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  430. XU M, Xu Y, Chen M, Li Y, et al
    Association study confirms two susceptibility loci for breast cancer in Chinese Han women.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  431. NUNES RA, Wray L, Mete M, Herbolsheimer P, et al
    Genomic profiling of breast cancer in African-American women using MammaPrint.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  432. SHIEH Y, Hu D, Ma L, Huntsman S, et al
    Breast cancer risk prediction using a clinical risk model and polygenic risk score.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  433. LI T, Mello-Thoms C, Brennan PC
    Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  434. LI N, Thompson ER, Rowley SM, McInerny S, et al
    Reevaluation of RINT1 as a breast cancer predisposition gene.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  435. LEE DH, Park S, Lim SM, Lee MK, et al
    Resting heart rate as a prognostic factor for mortality in patients with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available



  436. UK Breast Cancer Research Symposium 2016: Submitted Abstracts.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  437. ROGERS LQ, Courneya KS, Carter SJ, Anton PM, et al
    Effects of a multicomponent physical activity behavior change intervention on breast cancer survivor health status outcomes in a randomized controlled trial.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  438. VAN RAMSHORST MS, van der Heiden-van der Loo M, Dackus GM, Linn SC, et al
    Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  439. HARANO K, Lei X, Gonzalez-Angulo AM, Murthy RK, et al
    Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  440. VERSCHOOR AM, Kuijer A, Verloop J, Van Gils CH, et al
    Adjuvant systemic therapy in early breast cancer: impact of guideline changes and clinicopathological factors associated with nonadherence at a nation-wide level.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  441. GONG Z, Hong CC, Bandera EV, Adams-Campbell LL, et al
    Vigorous physical activity and risk of breast cancer in the African American breast cancer epidemiology and risk consortium.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  442. ALESKANDARANY MA, Abduljabbar R, Ashankyty I, Elmouna A, et al
    Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  443. FARVID MS, Cho E, Eliassen AH, Chen WY, et al
    Lifetime grain consumption and breast cancer risk.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  444. BAO T, Basal C, Seluzicki C, Li SQ, et al
    Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  445. PARSONS BM, Landercasper J, Smith AL, Go RS, et al
    21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  446. LI F, Armato SG, Giger ML, MacMahon H, et al
    Clinical significance of noncalcified lung nodules in patients with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  447. VALACHIS A, Garmo H, Weinman J, Fredriksson I, et al
    Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  448. FIGUEROA JD, Pfeiffer RM, Brinton LA, Palakal MM, et al
    Standardized measures of lobular involution and subsequent breast cancer risk among women with benign breast disease: a nested case-control study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  449. JOHANSSON H, Gandini S, Serrano D, Gjerde J, et al
    A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  450. NARAYAN AK, Visvanathan K, Harvey SC
    Comparative effectiveness of breast MRI and mammography in screening young women with elevated risk of developing breast cancer: a retrospective cohort study.
    Breast Cancer Res Treat. 2016;158:583-9.
    PubMed     Text format     Abstract available


  451. SLIJKHUIS WA, Noorda EM, van der Zaag-Loonen H, Eenennaam MJ, et al
    Ultrasound-guided breast-conserving surgery for early-stage palpable and nonpalpable invasive breast cancer: decreased excision volume at unchanged tumor-free resection margin.
    Breast Cancer Res Treat. 2016;158:535-41.
    PubMed     Text format     Abstract available


  452. BEEK MA, Gobardhan PD, Schoenmaeckers EJ, Klompenhouwer EG, et al
    Axillary reverse mapping in axillary surgery for breast cancer: an update of the current status.
    Breast Cancer Res Treat. 2016;158:421-32.
    PubMed     Text format     Abstract available


  453. HALPERN MT, Schrag D
    Effects of state-level medicaid policies and patient characteristics on time to breast cancer surgery among medicaid beneficiaries.
    Breast Cancer Res Treat. 2016;158:573-81.
    PubMed     Text format     Abstract available


    July 2016
  454. TABUNG FK, Steck SE, Liese AD, Zhang J, et al
    Patterns of change over time and history of the inflammatory potential of diet and risk of breast cancer among postmenopausal women.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  455. SCHOTT AF, Barlow WE, Van Poznak CH, Hayes DF, et al
    Phase II studies of two different schedules of dasatinib in ***bone metastasis predominant metastatic breast cancer: SWOG S0622.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  456. DONENBERG T, Ahmed H, Royer R, Zhang S, et al
    A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  457. LEOPOLD C
    Author's response to "letter to the editor: lower vitamin D status may explain racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer".
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  458. ALSHAREEDA AT, Negm OH, Aleskandarany MA, Green AR, et al
    Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  459. KEHL KL, Shen C, Litton JK, Arun B, et al
    Erratum to: Rates of BRCA1/2 mutation testing among young survivors of breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  460. GENNARI A, Amadori D, Scarpi E, Farolfi A, et al
    Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  461. ROGAN S, Taeymans J, Luginbuehl H, Aebi M, et al
    Therapy modalities to reduce lymphoedema in female breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  462. QIAN XL, Wen HY, Yang YL, Gu F, et al
    Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelines.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  463. GRANT WB
    Lower vitamin D status may explain racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  464. GREEN AR, Soria D, Powe DG, Nolan CC, et al
    Erratum to: Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  465. KWAN ML, Yao S, Lee VS, Roh JM, et al
    Race/ethnicity, genetic ancestry, and breast cancer-related lymphedema in the Pathways Study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  466. WARNER ET, Ballman KV, Strand C, Boughey JC, et al
    Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426).
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  467. MURANEN TA, Mavaddat N, Khan S, Fagerholm R, et al
    Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  468. LEE PE, Tierney MC, Wu W, Pritchard KI, et al
    Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  469. BATTAGLIA TA, Darnell JS, Ko N, Snyder F, et al
    The impact of patient navigation on the delivery of diagnostic breast cancer care in the National Patient Navigation Research Program: a prospective meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  470. LO-FO-WONG DN, de Haes HC, Aaronson NK, van Abbema DL, et al
    Predictors of enduring clinical distress in women with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  471. AHMAD A, Wang Z, Kong D, Ali S, et al
    Retraction Note to: FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  472. AHMAD A, Wang Z, Kong D, Ali R, et al
    Retraction Note to: Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-kappaB signaling pathways.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  473. BRENTNALL AR, Cuzick J, Byers H, Segal C, et al
    Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  474. YE ZJ, Liang MZ, Qiu HZ, Liu ML, et al
    Effect of a multidiscipline mentor-based program, Be Resilient to Breast Cancer (BRBC), on female breast cancer survivors in mainland China-A randomized, controlled, theoretically-derived intervention trial.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  475. ADAMS SC, Segal RJ, McKenzie DC, Vallerand JR, et al
    Impact of resistance and aerobic exercise on sarcopenia and dynapenia in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  476. SECRETO G, Sieri S, Agnoli C, Grioni S, et al
    A novel approach to breast cancer prevention: reducing excessive ovarian androgen production in elderly women.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  477. NAHLEH ZA, Barlow WE, Hayes DF, Schott AF, et al
    SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  478. ZHANG J, Sun J, Chen J, Yao L, et al
    Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  479. GARONA J, Alonso DF
    Perioperative biology in primary breast cancer: selective targeting of vasopressin type 2 receptor using desmopressin as a novel therapeutic approach.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  480. GIULIANI O, Mancini S, Puliti D, Caranci N, et al
    Patterns and determinants of receipt of follow-up mammography and/or clinical examination in a cohort of Italian breast cancer survivors.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  481. SOPIK V, Iqbal J, Sun P, Narod SA, et al
    Impact of a prior diagnosis of DCIS on survival from invasive breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  482. ALESKANDARANY MA, Green AR, Ashankyty I, Elmouna A, et al
    Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  483. YANG M, Teng W, Qu Y, Wang H, et al
    Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  484. VEERARAGHAVAN J, Ma J, Hu Y, Wang XS, et al
    Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  485. PRUNERI G, Gray KP, Vingiani A, Viale G, et al
    Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  486. KOTOULA V, Karavasilis V, Zagouri F, Kouvatseas G, et al
    Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


    June 2016
  487. VAN RAMSHORST MS, van der Heiden-van der Loo M, Dackus GM, Linn SC, et al
    The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  488. LAN ZJ, Hu Y, Zhang S, Li X, et al
    GGNBP2 acts as a tumor suppressor by inhibiting estrogen receptor alpha activity in breast cancer cells.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  489. LEOPOLD C, Wagner AK, Zhang F, Lu CY, et al
    Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  490. BRIGHT EE, Petrie KJ, Partridge AH, Stanton AL, et al
    Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  491. NYROP KA, Williams GR, Muss HB, Shachar SS, et al
    Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  492. FREEDMAN RA, Viswanath K, Vaz-Luis I, Keating NL, et al
    Learning from social media: utilizing advanced data extraction techniques to understand barriers to breast cancer treatment.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  493. SUH KJ, Ryu HS, Lee KH, Kim H, et al
    Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  494. TIWARI SR, Mishra P, Raska P, Calhoun B, et al
    Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  495. DOEBAR SC, van den Broek EC, Koppert LB, Jager A, et al
    Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  496. KUROZUMI S, Padilla M, Kurosumi M, Matsumoto H, et al
    HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  497. ZEITZER JM, Nouriani B, Rissling MB, Sledge GW, et al
    Aberrant nocturnal cortisol and disease progression in women with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  498. COLACINO JA, McDermott SP, Sartor MA, Wicha MS, et al
    Transcriptomic profiling of curcumin-treated human breast stem cells identifies a role for stearoyl-coa desaturase in breast cancer prevention.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  499. DILLEKAS H, Demicheli R, Ardoino I, Jensen SA, et al
    The recurrence pattern following delayed breast reconstruction after mastectomy for breast cancer suggests a systemic effect of surgery on occult dormant micrometastases.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  500. SMYTH LM, Iyengar NM, Chen MF, Popper SM, et al
    Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  501. HICKEY M, Marino JL, Braat S, Wong S, et al
    A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  502. KEINAN-BOKER L, Levine H, Derazne E, Molina-Hazan V, et al
    Measured adolescent body mass index and adult breast cancer in a cohort of 951,480 women.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  503. HIRKO KA, Fortner RT, Hankinson SE, Wu T, et al
    Plasma fluorescent oxidation products and risk of estrogen receptor-negative breast cancer in the Nurses' Health Study and Nurses' Health Study II.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  504. ARUN BK, Gong Y, Liu D, Litton JK, et al
    Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  505. WANG SY, Long JB, Killelea BK, Evans SB, et al
    Preoperative breast magnetic resonance imaging and contralateral breast cancer occurrence among older women with ductal carcinoma in situ.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  506. NEUGUT AI, Hillyer GC, Kushi LH, Lamerato L, et al
    A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL).
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  507. HEIN A, Gass P, Walter CB, Taran FA, et al
    Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  508. MATTER-WALSTRA K, Ruhstaller T, Klingbiel D, Schwenkglenks M, et al
    Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  509. GONG IY, Verma S, Yan AT, Ko DT, et al
    Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  510. MUNIZ J, Kidwell KM, Henry NL
    Associations between metabolic syndrome, breast cancer recurrence, and the 21-gene recurrence score assay.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  511. DI MEGLIO A, Freedman RA, Lin NU, Barry WT, et al
    Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  512. ROBLES AJ, Cai S, Cichewicz RH, Mooberry SL, et al
    Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  513. YAO H, Veine DM, Livant DL
    Therapeutic inhibition of breast cancer bone metastasis progression and lung colonization: breaking the vicious cycle by targeting alpha5beta1 integrin.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  514. AKINYEMIJU T, Moore JX, Ojesina AI, Waterbor JW, et al
    Racial disparities in individual breast cancer outcomes by hormone-receptor subtype, area-level socio-economic status and healthcare resources.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  515. ZHOU Y, Ouyang T, Xie Y, Wang T, et al
    A single-center, randomized, parallel controlled study comparing the efficacy and safety aspects of three anthracycline-based regimens as neoadjuvant chemotherapy in primary breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  516. SZALAYOVA G, Ogrodnik A, Spencer B, Wade J, et al
    Human breast cancer biopsies induce eosinophil recruitment and enhance adjacent cancer cell proliferation.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


    May 2016
  517. CHEN Y, Jiang L, Gao B, Cheng ZY, et al
    Survival and disease-free benefits with mastectomy versus breast conservation therapy for early breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  518. KWON JS, Pansegrau G, Nourmoussavi M, Hammond G, et al
    Long-term consequences of ovarian ablation for premenopausal breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  519. LIU YL, Saraf A, Lee SM, Zhong X, et al
    Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  520. LEWIN R, Sulkes A, Shochat T, Tsoref D, et al
    Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  521. WIRTZ RM, Sihto H, Isola J, Heikkila P, et al
    Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  522. CHEN L, Cook LS, Tang MC, Porter PL, et al
    Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  523. ORUCEVIC A, Heidel RE, Bell JL
    Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  524. BOQUIREN VM, Hack TF, Thomas RL, Towers A, et al
    A longitudinal analysis of chronic arm morbidity following breast cancer surgery.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  525. VILLARREAL-GARZA C, Bargallo-Rocha JE, Soto-Perez-de-Celis E, Lasa-Gonsebatt F, et al
    Real-world outcomes in young women with breast cancer treated with neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  526. ZHOU W, Zhao Y, Pan H, Li Q, et al
    Great tumour burden in the axilla may influence lymphatic drainage in breast cancer patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  527. SINGH K, Tantravahi U, Lomme MM, Pasquariello T, et al
    Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HE
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  528. SULAICA E, Han T, Wang W, Bhat R, et al
    Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  529. CHEN X, Hu H, He L, Yu X, et al
    A novel subtype classification and risk of breast cancer by histone modification profiling.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  530. HUO J, Smith BD, Giordano SH, Reece GP, et al
    Post-mastectomy breast reconstruction and its subsequent complications: a comparison between obese and non-obese women with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  531. JACOT W, Pons E, Frenel JS, Guiu S, et al
    Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  532. SCHMIDT N, Jacob L, Coleman R, Kostev K, et al
    Erratum to: The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  533. WISE R, Duhachek-Muggy S, Qi Y, Zolkiewski M, et al
    Protein disulfide isomerases in the endoplasmic reticulum promote anchorage-independent growth of breast cancer cells.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  534. BUSTREO S, Osella-Abate S, Cassoni P, Donadio M, et al
    Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  535. SUN F, Skolny MN, Swaroop MN, Rawal B, et al
    The need for preoperative baseline arm measurement to accurately quantify breast cancer-related lymphedema.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


    April 2016
  536. VAN ROOZENDAAL LM, Goorts B, Klinkert M, Keymeulen KB, et al
    Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy.
    Breast Cancer Res Treat. 2016;156:517-25.
    PubMed     Text format     Abstract available


  537. AUMANN K, Niermann K, Asberger J, Wellner U, et al
    Structured reporting ensures complete content and quick detection of essential data in pathology reports of oncological breast resection specimens.
    Breast Cancer Res Treat. 2016;156:495-500.
    PubMed     Text format     Abstract available


  538. EVANS CN, Brewer NT, Vadaparampil ST, Boisvert M, et al
    Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy.
    Breast Cancer Res Treat. 2016;156:549-55.
    PubMed     Text format     Abstract available


  539. LIM ST, Choi JE, Kim SJ, Kim HA, et al
    Prognostic implication of the tumor location according to molecular subtypes in axillary lymph node-positive invasive ductal cancer in a Korean population.
    Breast Cancer Res Treat. 2016;156:473-83.
    PubMed     Text format     Abstract available


    February 2016
  540. FAN YS, Casas CE, Peng J, Watkins M, et al
    HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Breast Cancer Res Treat. 2016;155:457-62.
    PubMed     Text format     Abstract available


  541. EVANS DG, Lalloo F, Howell S, Verhoef S, et al
    Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens.
    Breast Cancer Res Treat. 2016;155:597-601.
    PubMed     Text format     Abstract available


  542. CHIEN AJ, Cockerill A, Fancourt C, Schmidt E, et al
    A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
    Breast Cancer Res Treat. 2016;155:521-30.
    PubMed     Text format     Abstract available


  543. MILLER CL, Coopey SB, Rafferty E, Gadd M, et al
    Comparison of intra-operative specimen mammography to standard specimen mammography for excision of non-palpable breast lesions: a randomized trial.
    Breast Cancer Res Treat. 2016;155:513-9.
    PubMed     Text format     Abstract available


  544. SHAPIRO AC, Adlis SA, Robien K, Kirstein MN, et al
    Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
    Breast Cancer Res Treat. 2016;155:501-12.
    PubMed     Text format     Abstract available


  545. JONGEN L, Paridaens R, Floris G, Wildiers H, et al
    Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm.
    Breast Cancer Res Treat. 2016;155:603-7.
    PubMed     Text format     Abstract available


  546. KNOBF MT, Jeon S, Smith B, Harris L, et al
    Effect of a randomized controlled exercise trial on bone outcomes: influence of adjuvant endocrine therapy.
    Breast Cancer Res Treat. 2016;155:491-500.
    PubMed     Text format     Abstract available


  547. SHEFFIELD BS, Kos Z, Asleh-Aburaya K, Wang XQ, et al
    Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
    Breast Cancer Res Treat. 2016;155:483-90.
    PubMed     Text format     Abstract available


  548. HASSETT MJ, Jiang W, Habel LA, Nekhlyudov L, et al
    Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community.
    Breast Cancer Res Treat. 2016;155:541-9.
    PubMed     Text format     Abstract available


    January 2016
  549. BERTRAND KA, Burian RA, Eliassen AH, Willett WC, et al
    Adolescent intake of animal fat and red meat in relation to premenopausal mammographic density.
    Breast Cancer Res Treat. 2016;155:385-93.
    PubMed     Text format     Abstract available


  550. BISWAS S, Atienza P, Chipman J, Blackford AL, et al
    A two-stage approach to genetic risk assessment in primary care.
    Breast Cancer Res Treat. 2016;155:375-83.
    PubMed     Text format     Abstract available


  551. QUILES F, Menendez M, Tornero E, del Valle J, et al
    Investigating the effect of 28 BRCA1 and BRCA2 mutations on their related transcribed mRNA.
    Breast Cancer Res Treat. 2016;155:253-60.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: